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Abstract 
Following exposure to DNA damage, cells initiate a stress response 
involving multiple protein kinase signaling cascades. The DNA damage 
response results in one of several possible cell-fate decisions, or cellular 
responses: induction of cell-cycle arrest, initiation of DNA repair, activation of 
transcriptional programs, and either apoptosis, necrosis or cell senescence. The 
mechanisms by which cells make these decisions, and how cell fate depends 
upon variables such as DNA damage type and dose, and other environmental 
factors, is unknown. The process by which cells select among alternate fates 
following such stimuli, or "cues" is likely to involve a dynamic, multi-variate 
integration of signals from each of the kinase signaling components. A major 
goal of signal transduction research is to understand how information flows 
through signal transduction pathways downstream of a given cue, such as DNA 
damage, and how signals are integrated, in order to mediate cellular responses. 
Mathematical modeling approaches are necessary to advance our 
understanding of these processes. Indeed, statistical mining and modeling of 
large datasets, consisting of quantitative, dynamic signaling and response 
measurements, is capable of yielding models that identify key signaling 
components in a given cue-response relationship, as well as models that are 
highly predictive of cellular response following novel cues that perturb the same 
network. 
We have validated a novel assay system that allows for the high 
throughput collection of quantitative and dynamic signaling data for 7 protein 
kinases or phospho-proteins known to be "hubs" in the DNA damage response 
andlor general stress response networks, including ATM, Chk2, H2AX, JNK, p38, 
ERK and p53. This novel high-throughput In-cell Western assay is based on 
immuno-fluorescent staining and detection of target proteins in a "whole cell" 
environment, performed and visualized in a 96-well plate format. This assay 
allows for the detection and measurement of up to 7 target proteins in triplicate, 
over up to 3 treatment regimes, or up to 21 signals for a single treatment, 
simultaneously. Pre-processing steps, and steps involved in the protocol itself 
are significantly fewer (and require smaller amount of most reagents and 
biological material), as compared to traditional signal measurement methods, 
such as quantitative Western analysis and kinase assays. 
We have used this novel high-throughput In-cell Western assay to 
investigate the DNA damage response after the specific induction of DNA double 
strand breaks (DSB). We have measured the dynamics of seven "hub" proteins 
modified with activating phosphorylations (as a surrogate measure of protein 
activity) that span major branches of the DNA damage, stress, and death 
signaling networks, following the specific induction of DNA double strand breaks. 
Signaling proteins measured include ATM, Chk2, HZAX, JNK, p38, ERK and 
p53. In parallel with these signaling measurements, we have quantitatively 
measured corresponding phenotypic responses, such as cell cycle profile and 
apoptosis. 
In future work, we will use a Partial Least Squares (PLS) regression 
analysis approach to construct a statistical model using this data, which is 
predictive of the cellular responses included in our measurements, following 
perturbation of this branch of the DNA damage response network. This analysis 
should reveal key signaling components involved in the decision-making process 
(possible molecular targets for the improvement of cancer therapy regimens that 
rely upon the induction of DSB, e.g. the topoisomerase inhibitor, cisplatin), and 
provide a basis for constructing new, and improving existing, physico-chemical 
models of this branch of the DNA damage response network. 
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Title: Howard S. and Linda E. Stern Associate Professor of Biology and 
Biological Engineering and Assistant Professor of Biological Engineering 
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I. Introduction 
Signal transduction networks are extremely complex. They consist of 
highly inter-connected and redundant signaling pathways, which are constantly 
receiving input from intra- and extra-cellular cues. These overlapping and 
redundant pathways allow a cell to integrate a large amount of information 
regarding its extra-cellular environment and its intra-cellular status in order to 
make important decisions regarding its fate. Such cell decisions may depend on 
multiple "cues" such as extra-cellular growth factors or intracellular viral antigens. 
The relationship between any received cue and the phenotypic response of the 
cell resulting from that cue is determined by the overall state of the signal 
transduction network at the time the cue is received. In other words the state of 
the network determines how information flows through it. 
A major goal of research in signal transduction is to understand how 
information flow through a network results in a given outcome. In order to 
understand the cell decision process, it is necessary to follow information flow 
("signals") through various network states following perturbations to that network 
("cues") and to record the resultant corresponding phenotypes ("responses"). 
From this data, it should be possible to extract the features of the information 
flow that were influential in mediating those phenotypes. 
Many signaling molecules participate in signal transduction networks, and 
it is not possible or necessary to measure them all. Instead it is more efficient to 
measure the signals in the network that are most likely to carry critical 
information that will influences the decision-making processes. For certain cue- 
response pairs, many of the influential signaling molecules may be known. For 
example, Akt is a critical signaling molecule in mediating survival ("response") 
after exposure of cells to insulin ("cue") (Janes, Albeck et al. 2003). 
I. Mathematical Modeling as an Approach to Biological Problems 
The relationship between the signaling information and the resultant 
phenotypes is complex and non-intuitive, and analysis of data relating network 
states to outcomes requires mathematical modeling approaches. Partial least 
squares regression analysis (PLS) has been applied to data extraction problems 
in fields ranging from meteorology to sociology. PLS is capable of finding 
statistically significant inter-relationships between dependent and independent 
variables in multivariate data-sets when the number of independent variables is 
large and relationships are no longer intuitive. PLS is effective at "reducing 
dimensionality"; that is, PLS identifies a few factors or combinations of factors 
that are important in the determination of the dependent variable, out of a very 
large number of input parameters in the model. PLS can be thought of as a 
modification or extension of multiple linear regression analysis (MLR), but differs 
from MLR in several ways (Tobias). MLR gives a linear relationship between a 
dependent variable and a large number of independent variables, producing a 
weighting matrix of factors relating the dependent variable to the independent 
variables that is of the same rank as the number of input independent variable 
(the manifest factors). If the number of independent variables is greater than the 
number of observations in the data set, this type of regression analysis will tend 
to over-fit the data as not all manifest factors accounting for the variation in the 
sample used to train the model will significantly account for variation in the 
population from which the sample was drawn. Thus the model will well fit the 
training data, but may lack predictive ability for new data. In the case where the 
number of independent variables is greater than the number of observations in 
the data set, PLS is a more appropriate analysis technique. PLS is capable of 
finding a reduced set of underlying, or latent, factors, that may also be 
combinations of manifest factors, and that account for most of the manifest 
variation in response (Tobias; Janes, Kelly et al. 2004). These latent factors are 
expected to significantly account for the variation in the dependent variables and 
the covariation between these inter-independent variable variations and the 
dependent variable in the sample data and in the population from which the 
sample data was taken. A model constructed using PLS is therefore expected to 
have predictive capabilities for new data under these conditions (Tobias). 
PLS and MLR analyses require large amounts of quantitative, 
reproducible data as input. A caveat on the predictive capability of a model 
constructed using PLS is that the original model must be sufficiently trained to 
accommodate such predictions. That is, in order for the model's predictive ability 
to be robust, it must encompass signaling data from cues that highly perturb the 
network and result in highly variable response phenotype in order to stretch the 
dynamic range of each of the measured network signaling and response 
components(Gaudet, Janes et al. 2005). 
Since many proteins participate in signal transduction networks 
downstream of any given cue that mediates a response, the trajectory of their 
activity between the time of the cue and the mediated response is important in 
determining what that response will be. Thus, it is necessary to collect 
quantitative, dynamic data regarding the activity of the important molecules in the 
signal transduction network following various cues that perturb the network to 
lead to differential phenotypes. In addition, the model will also require 
quantitative data regarding the corresponding phenotypic outcome. In such a 
model, the signaling data are the independent variables and the responses are 
the dependent variables. 
Janes et al. pioneered the application of PLS to biological problems in 
their analysis of a data set of protein measurements in the context of TNF- 
induced apoptosis (Janes, Albeck et al. 2003). Janes et al. developed a 
heterogeneous set of assays capable of measuring levels andlor activities of 20- 
30 intracellular signals thought to be important in the cytokine response network 
under study (Janes, Albeck et al. 2003; Janes, Kelly et al. 2004). These included 
kinase assays, quantitative westerns, and antibody arrays. Many assays 
concentrated on direct measurement of kinase activity or on indirect 
measurement of the same by measurement of levels of kinase modified with 
activating phosphorylations, since protein kinases are some of the most 
important molecular mediators in signal transduction events and are expected to 
carry much of the information that is influential in cell decision processes. 
Janes et al rigorously showed that these assays generated data that was 
quantitative and reproducible both over time, and between assays (Janes, Kelly 
et al. 2004; Gaudet, Janes et al. 2005). With these data, Janes et al. constructed 
extremely accurate predictive models of apoptotic response to various cytokine 
cues in HT-29 cell lines. These models exceeded the expectations of the 
investigators, and were capable even of predicting the apoptotic response of a 
different cell type to various cytokine cues (a model trained on the HT-29 cell line 
signal-response is able to predict HeLa cell line response) as well as the 
apoptotic response of this cell type to a cue of a completely different character (a 
model trained on cytokinelmitogen stimulation is able to predict response to an 
invading pathogen such as adenovirus). 
11. Project Goals 
In the current project, we had two major goals: 
- To develop an In-cell Western (ICW)-based assay system that will allow 
the measurement of signaling dynamics in a high throughput, quantitative 
and reproducible manner 
- To use this assay system to study the signaling dynamics specifically 
involved in the cellular response to DNA double strand breaks (DSB) and 
to collect data for future construction of a predictive statistical model using 
the PLS methods 
111. DNA damage response 
DNA damage is an intracellular "cue" that results in perturbation of signal 
transduction networks and leads to cell fate decisions. Following exposure to 
DNA damage, cells initiate a stress response involving multiple protein kinase 
signaling cascades (Fig. 1). The DNA damage response results in one of several 
possible cell-fate decisions: induction of cell-cycle arrest, initiation of DNA repair, 
activation of transcriptional programs, and either apoptosis, necrosis or cell 
senescence (Khanna and Jackson 2001 ; Zhou and Bartek 2004). The 
mechanisms by which cells make these decisions are not known. 
It is widely accepted that DNA damage causes cancer (Khanna and 
Jackson 2001; Kastan and Bartek 2004). In addition, intentional damage to the 
DNA of tumor cells is used to treat cancer (Baldwin and Osheroff 2005), and the 
inadvertent damage to non-tumor cells is partially responsible for the side effects 
associated with cancer treatment (Allan and Travis 2005). Cellular DNA is 
constantly being damaged as a result of attack by endogenous and exogenous 
sources (e.g. oxygen radicals produced in metabolic processes and 
environmental ionizing radiation respectively) and as a result of normal DNA 
replication. Therefore, a greater understanding of how information flow through 
DNA damage signaling networks mediates cell decision processes regarding fate 
is highly relevant to the prevention and effective treatment of human cancer. 
DNA can be damaged in many ways, leading to a variety of lesions that 
are thought to have specific sensors. Signals arising from these specific sensors 
are integrated into the general DNA damage signaling network. Most treatments 
used to induce DNA damage (clinically or experimentally) produce a broad 
spectrum of lesions, and so responses to general types of treatments have been 
better characterized than responses to specific lesions. The cellular response to 
ionizing radiation (IR) and ultraviolet radiation (UV) are perhaps the best studied. 
The SerineIThreonine Pl(3) Kinase-like kinases (PIKKs) ATM (Ataxia- 
telangiectasia mutated) and ATR (Ataxia-telangiectasia and RAD3-related) are 
among the most proximal players in response to IR and UV-induced DNA 
damage (Tibbetts, Brumbaugh et al. 1999; Klein, Muijtjens et al. 2000), possibly 
even serving to directly sense DNA damage (Khanna and Jackson 2001 ; Kastan 
and Bartek 2004). Following IR treatment, ATM, which exists in the nucleus as a 
resting homodimer, is the PlKK that is preferentially activated in a multi-step 
process that is necessary for full activation (Tibbetts, Brumbaugh et al. 1999). 
This process involves intermolecular auto-phosphorylation on Ser-1981, 
dissociation of ATM-homodimers, and localization of monomeric ATM to sites of 
damage on the DNA (Bakkenist and Kastan 2003). Activated ATM in turn serves 
to activate the downstream effector kinase Chk2 on Thr-68 (Matsuoka, Rotman 
et al. 2000; Zhou, Chaturvedi et al. 2000; Bartek and Lukas 2003). ATM also 
participates in the activation of the p53 transcription factor by phosphorylation of 
p53 on Ser-15 (Caspari 2000). Following UV treatment, ATR is preferentially 
activated (Tibbetts, Brumbaugh et al. 1999). Under normal cellular conditions, 
ATR is found in complex with ATRlP (ATR-interacting protein), a small interacting 
protein with a considerable affinity for replication protein A (RPA) (Cortez, 
Guntuku et al. 2001; Unsal-Kacmaz and Sancar 2004). Unlike ATM, the intrinsic 
kinase activity of ATR is not greatly increased following DNA damage. The 
increased functional activity of ATR under these conditions is, instead, likely to 
be the result of the localization of ATR to sites of DNA damage, via the affinity of 
complexed ATRIP, for RPA that coats ssDNA at sites of DNA damage either 
before or after processing of the lesion (Zou and Elledge 2003). Once activated, 
ATR serves to phosphorylate the downstream effector kinase Chkl on Ser-317 
and Ser-345 (Lopez-Girona, Tanaka et al. 2001 ; Zhao and Piwnica-Worms 
2001). The small Chkl-interacting protein, Claspin, is required for the ATR- 
mediated phosphorylation and activation of Chkl (Lee, Gold et al. 2005). 
Claspin binds RPA and chromatin; it binds to Chkl when it has been dually 
phosphorylated on Ser-864 and Ser-895 and it is likely required to bring Chkl 
into close proximity with ATR (Jeong, Kumagai et al. 2003). ATR is also 
activated in response to IR, although probably later and not as strongly as ATM; 
in the absence of ATM, ATR can partially compensate for its function by 
phosphorylating and activating downstream targets of ATM (Cliby, Roberts et al. 
1998; Kim, Lim et al. 1999). Additionally, ATR localizes to sites of collapsed 
replication forks, and seems to be required for regulation of normal cell cycle 
progression (Cobb, Schleker et al. 2005). In the absence of ATR, ATM is unable 
to compensate, and ATR(-I-) mutants are embryonic lethal (Klein, Muijtjens et al. 
2000). 
Chkl and Chk2 play a key role in mediating cell cycle arrest in G I  and 
G2lM following DNA damage by phosphorylating CDC25 family members. Chkl 
is thought to mediate a G I  arrest through phosphorylation of CDC25A, targeting 
it for ubiquitination and degradation (Bulavin, Amundson et al. 2002; Ho, Siu et 
al. 2005). Phosphorylation of CDC25B or CDC25C by Chkl and Chk2 also 
results in a 14-3-3 binding site and cytoplasmic sequestration required for the 
induction of a G2lM arrest following IR (O'Connell, Walworth et al. 2000). Chkl 
and Chk2 (in addition to ATM and ATR) also phosphorylate p53 (Caspari 2000). 
p53 participates in the long term maintenance of cell cycle arrest, by 
transcriptionally upregulating the cdk inhibitor p21 and other factors, as well as 
the induction of apoptosis (Vousden 2000; Appella and Anderson 2001 ; Yoon, 
Chen et al. 2003; Yoon and Yang 2004). It has been shown recently by the Yaffe 
lab and the Fornace lab that the p38 SAPK pathway is activated following UV 
treatment, and it has been proposed that p38 activation of MAPKAPK2lChk3 acts 
as another branch in the DNA damage response, in analogy to the ATM-Chk2 
and ATR-Chkl branches. Indeed, MAPKAPK2lChk3 shares a high functional 
similarity to the other Chk effector kinases in mediating cell cycle arrest following 
UV (Manke, Nguyen et al. 2005). MAPKAPKZlCHK3 has been shown to 
phosphorylate CDC25BIC following UV, generating the 14-3-3 binding site 
necessary for cytoplasmic sequestration, and it has been shown that loss of 
MAPKAPK2lChk3 results in an inability to sustain a G21M or a Gl lS checkpoint 
following UV-induced DNA damage (Manke, Nguyen et al. 2005). 
Rapid response of the DNA damage signaling network is mediated by 
post-translational modifications which lead to rapid activation, localization and 
degradation of various signaling components (Appella and Anderson 2001 ; 
Kastan and Bartek 2004). Maintenance of these initial responses (e.g. the 
maintenance of a cell cycle checkpoint in order to allow for on-going DNA repair) 
requires transcriptional up-regulation of signaling components; transcriptional 
upregulation of p21, for example, is required for maintenance of the G I  
checkpoint (Appella and Anderson 2001 ; Yoon, Chen et al. 2003; Kastan and 
Bartek 2004; Yoon and Yang 2004). 
Although some DNA damaging chemotherapeutic agents (particularly 
topoisomerase inhibitors, such as doxorubicin (DOX)) cause other types of DNA 
damage to a certain extent, it is thought that the ability of these agents to kill 
cancer cells is due mainly to their ability to induce DNA double strand breaks 
(DSB) (Khanna and Jackson 2001 ; Baldwin and Osheroff 2005). Here, we used 
calicheamicin (CLM), an enediyene antibiotic agent that is capable of specifically 
inducing DSB without other known types of DNA damage (Elmroth, Nygren et al. 
2003; Prokop, Wrasidlo et al. 2003)' to study cellular signaling and response 
pathways downstream of this type of DNA lesion. 
IV. Calicheamicin (CL M) 
Calicheamicin (CLM) is a naturally occurring enediyne anti-cancer 
antibiotic that was first discovered in the fermentation broth of Micromonospora 
echinospora ssp. Calichensis (Fig. 2A) (Liang)). CLM potently and specifically 
induces DNA double strand breaks (DSB). The mechanism for the specificity of 
the lesion created by CLM has been extensively investigated. Attack of the 
central sulfur atom of the CLM tri-sulfide group by a nucleophile (such as 
glutathione) results in a conformational change in the structure of the CLM 
molecule. This conformational change places strain on the lo-membered 
enediyene-containing ring, which is completely relieved when the enediyene 
undergoes the Bergman cyclization reaction (Fig. 2B) (Nicolaou, Smith et al. 
1993). An intermediate of this cyclization reaction is a highly reactive benzenoid 
diradical that, when CLM is docked to DNA is a site-specific manner, abstracts 
hydrogen atoms from one DNA strand at the C-5' position of the 5' cytidine in 5'- 
TCCT-3', and from the C-4' position of the nucleotide on the complementary 
strand three base pairs removed on the 3'side. This results in the cleavage of 
both strands of DNA (Nicolaou, Smith et al. 1993). The chemical structure of the 
DNA lesion remaining on each of the DNA strands following CLM attack is 
determined by the position at which it has been attacked (4' C on one strand, 5' 
C on adjacent strand). 4'-deoxyribose chemistry frequently leads to strand 
breaks and abasic sites on the DNA and 5'-deoxyribose chemistry can lead to 
strand breaks with bulky lesions (M.S. DeMott, private communication) (Lopez- 
Larraza, Moore et al. 2001 ; Chen, Bohnert et al. 2004). Once the reaction has 
taken place, the CLM enediyne function is lost; thus no further DNA may be 
cleaved. 
CLM appears capable of inducing DSB far more specifically than other 
methods of DSB induction used either experimentally to study the DSB response 
or clinically to treat various cancers, with some sources citing percentages of 
CLM-induced DNA damage in the form of DSB as high as 95% (Lopez-Larraza, 
Moore et al. 2001). The relative rates of DNA double strand break (DSB) and 
DNA single strand break (SSB) induction for several DNA damaging agents are 
listed in Table 1 (Nicolaou, Smith et al. 1993; Banath and Olive 2003; Ismail, 
Nystrom et al. 2005). 
Table 1 
This specificity for DSB induction is desirable experimentally as it allows 
the signaling response to DSB to be evaluated independent of the signaling 
response to other DNA lesions such as single strand breaks (SSB) and base 
damage, or the signaling response to damage to other cellular components such 
as proteins and lipids. 
DNA damaging agent 
Calicheamicin 
Bleomycin 
X-rays 
y-I R 
4-nitro-quinoline-N-oxide 
Hydrogen peroxide 
In vitro, CLM treatment of a wide range of cell lines results in strong DSB 
response and cell cycle arrest (Elmroth, Nygren et al. 2003) as well as a potent 
induction of cell death. CLM has highly variable levels of cytotoxicity depending 
on cell-line, with IC50s ranging from femtomolar (fM) to micromolar (pM) 
concentrations in a panel of 11 tumor cells lines tested (Nicolaou, Smith et al. 
1993). It also shows preferential cytotoxicity in tumor cell lines over normal cell 
lines. In a panel of 4 normal cell lines tested, including bone marrow and dermal 
fibroblast cells that frequently experience bystander effects from 
chemotherapeutic regimens, measured IC50s were micromolar (pM) and higher. 
This preference may prove clinically useful. Cell death following CLM treatment 
seems to proceed largely by apoptosis (Nicolaou, Smith et al. 1993), though it 
has also been observed in some cell types that death can occur by mitotic 
catastrophe; this involves the accumulation of aneuploid cells that undergo 
several abnormal mitoses without cell division before dying (in vitro and in vivo 
observation ) (Mekid, Tounekti et al. 2003). 
SSB:DSB 
2: 1 
5: 1 
20: 1 
1 00: 1 
100: 1 
1 000: 1 
Clinically, it has been shown that most tumor cell death following 
treatment with DNA damaging chemotherapeutics is due to the induction of DSB, 
and it is widely accepted that DSB are the most cytotoxic of DNA lesions 
(Khanna and Jackson 2001), so chemotherapeutics that can specifically induce 
DSB may be expected to be highly efficacious in cancer treatment. Indeed, 
treatment with CLM has been shown to increase survival in mice injected with 
tumor cell lines (Nicolaou, Smith et al. 1993). CLM linked to targeting antibodies 
has also been shown effective against acute myeloid leukemia, renal cell 
carcinoma and ovarian cancer (Elmroth, Nygren et al. 2003). As such, CLM is a 
specific inducer of DNA double strand breaks that is expected to be a highly 
valuable tool in the laboratory and in the clinic. 
V. DSB Signaling and Response 
Here we investigated the effects of calicheamicin treatment on DNA 
damage signaling and cellular response. We chose to measure seven signals 
(as allowed by our assay format, discussed in section VII) involved, or 
hypothesized to be involved in, the cellular signaling and response to DSB: 
phospho-ATM (Ser-1981), phospho-H2AX (Ser-139), phospho-Chk2 (Thr-68), 
phospho-p53 (Ser-15), phospho-p38 (Thr-182/Tyr-184), phospho-JNK (Thr- 
183/Tyr-185), and phospho-ERK (Thr-180TTyr-182). 
As discussed previously, ATM is a PI(3)Kinase-like kinase that is thought 
to be one of the most proximal signals activated following induction of IR-induced 
DSB (Burma, Chen et al. 2001). It is very important for primary signal 
transduction to effector kinases, such as Chk2, and to transcription factors, such 
as p53. ATM also phosphorylates H2AX on Ser-139 (Burma, Chen et al. 2001 ; 
Friesner, Liu et al. 2005). ATM deficient cells are highly sensitive to radiation 
and to chemotherapeutic agents that cause DSB (Taylor and Byrd 2005). 
H2AX phosphorylation is one of the first measurable responses to DSB 
(Celeste, Fernandez-Capetillo et al. 2003). It becomes phosphorylated on Ser- 
139 and is incorporated into a 2Mb region surrounding a break and can be 
visualized in microscopic foci (Burma, Chen et al. 2001 ; Banath and Olive 2003). 
It is thought to be important in stabilizing the characteristic multi-protein 
complexes that form at sites of DSB. The stabilization of these foci is necessary 
for activation and coordination of repair and checkpoint proteins (Celeste, 
Fernandez-Capetillo et al. 2003; Mochan, Venere et al. 2004). Mice lacking 
H2AX have cell-cycle checkpoint defects and pre-disposition to cancer. H2AX is 
also located in a cytogenetic region that is commonly mutated in human cancers 
(1 1 q23) (Bassing, Heikyung et al. 2003). 
Chk2 is the primary effector kinase known to be activated by ATM by 
phosphorylation at Thr-68 (Matsuoka, Rotman et al. 2000; Zhou, Chaturvedi et 
al. 2000). As previously discussed, it is an important player in mediating cell 
cycle arrest in both G I  and G2/M via phosphorylation of CDC25 family members 
(O'Connell, Walworth et al. 2000). It has also been implicated in promoting 
apoptosis (Takai, Naka et al. 2002). 
p53 is a transcription factor that is implicated both in promoting apoptosis 
in response to a wide variety of stresses, including genotoxic stress, and in 
maintenance of cell cycle arrest responses (Giaccia and Kastan 1998; Prives and 
Hall 1999; Vousden 2000). It is a substrate for ATM and ATR on Ser-15 and for 
Chkl and Chk2 on Ser-20 (Caspari 2000). 
p38, JNK and ERK kinases are all MAPK members of the MAPK (Mitogen 
Activated Protein Kinase) family. While MAPK family members are not 
traditionally thought of as part of the specific DNA damage, or DSB, response, 
these important cellular proteins are widely accepted to be key elements in the 
regulation of cell fate decisions such as cell cycle control and apoptosis in nearly 
all cell types, and they undoubtedly play a role in regulation of cell fate following 
genotoxic stress. The MAPK family of signaling pathways is eukaryotic-specific 
and highly conserved (Orton, Sturm et al. 2005) (Chang and Karin 2001) 
(Sumbayev and Yasinska 2005). This family of signaling pathways consists of 
several specific pathways all sharing a general three-kinase signal cascade 
format in which a MAPKKK (MAPK kinase kinase) serinelthreonine kinase is 
activated, dually phosphorylates and activates a MAPKK (MAPK kinase) dual 
specificity kinase, that, in turn, dually phosphorylates and activates a MAPK 
(MAP kinase) serinelthreonine kinase on a TXY motif in the MAPK activation 
loop (Yung, Dolginov et al. 1997) (Chang and Karin 2001). MAPKs are serine- 
threonine kinases with a repertoire of at least 80 substrates consisting of 
transcription factors, protein kinases and cytoskeletal components (Fritz and 
Kaina 2005). There are relatively few MAPKs, just five, the best characterized in 
mammals being p38, JNK, and ERKI 12. However, they are involved in the 
mediation of such wide-ranging and key cellular processes as cellular growth, 
differentiation, adaptation to stress, survival and death in response to such 
diverse stimuli as growth factors, cytokines, cellular adherence status and 
hypoxic and genotoxic stress (Orton, Sturm et al. 2005) (Chang and Karin 2001). 
The ability of these few kinases to respond to such a wide variety of stimuli is not 
fully understood, but is probably facilitated by the MAPK cascade set-up and the 
ability of several MAPKKK to initiate each cascade (Chang and Karin 2001). 
ERK(112) is the MAPK downstream in the three-kinase MAPK pathway 
consisting of RaflMEKIERK (Bose, Motiwale et al. 2005). ERK is activated by 
the MAPK kinases MEKI and MEK2 in response to such growth factors as EGF 
and PDGF (Widmann, Gibson et al. 1999; Chang and Karin 2001). Its role in the 
regulation of cell proliferation and differentiation in response to various growth 
factors and mitogenic signals is well established (Bose, Motiwale et al. 2005). 
However, it is also implicated in both cell cycle control and protection from cell 
death in some cell types (Widmann, Gibson et al. 1999; Chang and Karin 2001), 
and it is activated in cells following treatment with several genotoxic agents 
(Solhaug, Refsnes et al. 2004) (Bose, Motiwale et al. 2005). We hypothesize 
that ERK participates in regulation of cell fate decisions regarding cell cycle 
control and cell death in response to the induction of DSB. 
p38 is a MAPK family member that is activated by the MAPK kinases 
MEK3 and MEK6 (Widmann, Gibson et al. 1999) in response to cellular stresses, 
such as genotoxic and osmotic stress, and' inflammatory cytokines, such as TNF- 
a and IL-I (Deacon and Blank 1997). Its known substrates include the 
transcription factor ATF2 and the protein kinase MAPK activated protein kinase-2 
(MAPKAPK2lChk3) (Deacon and Blank 1997) (Manke, Nguyen et al. 2005). p38 
has a role in mediating cytokine production and apoptosis (Chang and Karin 
2001; Sumbayev and Yasinska 2005), as well as in cell cycle checkpoint 
induction and apoptosis following DNA damage (Manke, Nguyen et al. 2005) 
(Fritz and Kaina 2005). We hypothesize that p38 participates in regulation of cell 
fate decisions regarding cell cycle control and cell death in response to the 
induction of DSB. 
JNK is a MAPK family member that is activated by the MAPK kinases 
MEK4 and MEK7 (Widmann, Gibson et al. 1999) in response to such cellular 
stresses as genotoxic (eg UV light, y-irradiation) and osmotic stess, and in 
response to inflammatory cytokines, such as TNF-a and IL-I ) (Solhaug , Refsnes 
et al. 2004) (Bose, Motiwale et al. 2005) (Xia, Makris et al. 2000) (Sumbayev and 
Yasinska 2005) (Fritz and Kaina 2005). Its known substrates include the Jun- 
family transcription factors (c-Jun, c-Fos, ATF2) (Chang and Karin 2001 ; Fritz 
and Kaina 2005). JNK is implicated in the induction of apoptosis in several cell 
types (Sumbayev and Yasinska 2005) (Chang and Karin 2001) (Fritz and Kaina 
2005). We hypothesize that JNK participates in regulation of cell fate decisions 
regarding cell death in response to the induction of DSB. 
In addition to these cellular signals, we also measured the cellular,response 
to CLM in several ways. We quantified the extent of cell death (cleaved 
caspase-3 detection and sub-GI DNA content population) and cell cycle profiles 
(relative PI incorporation) in populations of cells following DSB induction. These 
cellular responses were measured by direct DNA or immuno-staining and 
subsequent FACS (fluorescence assisted cell sorting) analysis. 
VI. In-Cell Western Assay (IC W )  
Janes et al. gathered protein signaling data to build a data set appropriate 
for statistical modeling approaches such as partial least squares regression 
analysis (PLS) using several assay approaches, including kinase activity assays, 
quantitative immunoblots and antibody micro-arrays. There are several 
drawbacks to each of these approaches: Each of these assays requires several 
pre-processing steps before they may be performed, and are themselves non- 
trivial, multi-step protocols. Initial validation of kinase activity assays and of 
antibody micro-array assays is as well an arduous process, and all of these 
assay protocols require considerable amounts of biological material and 
reagents. The development of an alternative andlor additional assay for the 
rapid collection of quantitative, dynamic protein signaling data is highly desirable. 
The In Cell Western (ICW) assay provides a high throughput way to 
gather quantitative, dynamic signaling data. This assay format allows for the 
measurement of up to 7 signals in triplicate, in response to up to three treatment 
regimes, or the measurement of up to 21 signals in triplicate after a single 
treatment. It offers distinct advantages over other assay systems which have 
been used in the measurement of signaling dynamics. Almost no pre-processing 
of the samples is required and the protocol itself consists of far fewer processing 
steps for each measurement than traditional western analysis or kinase activity 
assays. Smaller reagent quantities and less biological material is required to 
obtain measurements. 
In the ICW assay, cells are first seeded and grown in a 96-well plate 
format. Cells are treated with the appropriate cue, fixed, permeabilized and 
immuno-stained in the same 96-well plate. Bound primary antibodies are 
detected and prepared for visualization by incubation with lRDye 800CW- 
conjucated secondary antibodies, which are conjugated to dye molecules with 
absorption and emission maxima in the infrared range. Stained cells are then 
visualized using an Odyssey IR scanner. The scanner has two solid state lasers 
with excitation wavelengths of 680 and 780nm. Absorption maxima of the dyes 
conjugated to the secondary antibodies are closely matched to these excitation 
wavelengths (Alexa fluor-680 conjugated secondary antibodies and Topro-3 
Iodide DNA stain are excited with the 680nm laser, with absorbance maxima 
respectively of 679nm and 642nm; IRDye800CW conjugated secondary 
antibodies are excited with the 800nm laser, with absorbance maxima at 774nm). 
Because the emission maxima of the dyes excited by the two lasers are narrow, 
and separated by about 1 OOnm, signal overlap is minimized. 
The two lasers simultaneously excite each point on the scanner bed 
surface during a scan. Light from both fluorescing infrared dyes is collected by a 
microscope objective focused on the point of excitation. Light is passed to a 
dichroic mirror that transmits light above 810nm and reflects light below 750nm to 
split the light into two signals. The two signals are then received by two 
physically separated silicon avalanche diodes. Each light signal is translated into 
a detectable current and given a pseudo-color intensity that is directly 
proportional to the measured current (red for the light collected from excitation 
with the 680nm laser and green for light collected from excitation with the 780nm 
laser) (LiCor Biosciences, 2005). 
The ability of the Odyssey scanner to detect signal from dyes fluorescing 
in the IR range is directly responsible for its ability to deliver sensitive, 
quantitative and reliable data. Chemi-luminescent detection methods offer an 
indirect enzymatic detection of primary antibody bound. This detection is highly 
dependent upon both reaction start time and exposure time, preventing accurate 
quantitation of primary signal. In contrast, every IR-dye conjugated antibody 
fluoresces when excited by the Odyssey laser, allowing for a more linear 
response and accurate quantitation of signal (LiCor Biosciences, 2005). Use of 
IR wavelengths offers a distinct advantage over methods using fluorescence in 
the visible wavelengths, which are hampered by auto-fluorescence from both 
plates and cells. 
We have validated this assay system for the simultaneous measurement 
of seven signals that are expected to be informative nodes in the cellular DSB 
response. 
II. Materials and Methods 
I. Antibodies and Reagants 
Primary Phospho-Specific Antibodies: 
Antigen detected, animal source, lot #, source, catalog #; dilution used 
p38, Thr-180TTyr-182, rabbit polyclonal, lot # I  4, CST, 
catalog #9211; 1 : 100 
ATM, Ser-1981, mouse monoclonal, lot#24675, Upstate, 
catalog #05-740; 1 :500 
H2AX, Ser-139, rabbit polyclonal, lot #2, CST, catalog 
#2577; 1:200 
Chk2, Thr-68, rabbit polyclonal, lot #5, CST, catalog #2661; 
1 :250 
p53, Ser-15, rabbit polyclonal, lot #6, CST, catalog #9284; 
1 :500 
JNK, Thr-183TTyr-185, rabbit polyclonal, lot #8, CST, catalog 
#9251; 1:lOO 
ERK, Thr-202/Tyr-204, rabbit monoclonal, lot #2, CST, 
catalog #4377; 1 : 1 00 
H3, Ser-I 0, rabbit polyclonal, lot #, Upstate, catalog #, 1 : 
Primary Non-Phospho Antibodies: 
Antigen detected, source; dilution used 
Anti-Cleaved caspase-3, BD #559565; 1 :500 
Secondary Antibodies: 
Antigen detected, source; dilution used 
800CW IR-Dye Goat anti-Rabbit, Rockland; 1 :500 
800CW IR-Dye Goat anti-Mouse, Rockland; 1 :500 
800CW IR-Dye Donkey anti-Mouse, Rockland; 1 :500 
Alexa fluor 647-conjugated Donkey anti-Rabbit IgG, 
Molecular Probes; 1 :250 
Alexa fluor 488-conjugated Goat anti-Rabbit IgG, Molecular 
Probes; 1 :30 
DNA Stain: 
Topro-3 Iodide, Molecular Probes; 1 :2500 
Propidium Iodide (PI), Sigma (10mglml in PBS) 
Other Reagants and Materials: 
Calicheamicin (CLM), generous gift of Pete Dedon and M. 
DeMott (100uM in MeOH) 
Doxorubicin, Sigma (1 0mM in water) 
Odyssey Blocking Buffer, Licor 
PMA, phorbol 12-myristate 13-acetate, Sigma (5mglml in 
EtOH) 
11. Antibody Validation Experiments 
Cell culture conditions for Ab dilution experiments (Fig. 3): 
In order to determine optimal antibody concentrations for primary 
antibodies, tissue culture treated 96-well plates were seeded with U20S cells at 
10,000 cells per well in 200ul total volume of DMEIHEP media supplemented 
with 10% FBS, 1 % penicillinlstreptomycin, and 1 % glutamine (total media). Edge 
wells were not seeded with cells but received the same total volume of media as 
other wells. Wells were covered immediately with low-evaporation membranes in 
addition to plate tops and incubated overnight at 37°C. 
Cell culture conditions for Cell number dilution experiments (Fig. 4): 
In order to assay for linearity of primary antibody binding, tissue culture 
treated 96-well plates were seeded with U20S cells as follows: Wells in Row B 
(wells 82-81 1) were seeded at 10,000 cells per well in 200ul total volume of 
DMElHEP media supplemented with 10% FBS, 1 % penicillinlstreptomycin, and 
1 % glutamine (total media). Wells in Row C (wells C2-CAI) were seeded at 
8,000 cells per well in 200ul total media. Rows Dl E, F and G were seeded at 
6,000 cellslwell, 4,000 cellslwell, 2,000 cellslwell and no cells respectively. Edge 
wells received the same total volume of media as other wells but were not 
seeded. Wells were covered immediately with low-evaporation membranes in 
addition to plate tops and incubated overnight at 37°C prior to experiments. 
--Treatment and fixation- 
ATM, Chk2, H2AX (100nM CLM): 
In order to evaluate primary antibodies with specificity for active forms of 
ATM, Chk2 and H2AX, cells were treated with 100nM calicheamicin in total 
media or with control media and incubated at 37°C for 15 minutes before fixation 
with 4% formaldehyde in PBS. Briefly, IOOuM calicheamicin (CLM) stock in a 
MeOH carrier was diluted 1000-fold in total media for a final treatment 
concentration of 100nM CLM. Control media consisted of an equivalent volume 
of 100% MeOH diluted in total media. Media was aspirated from two consecutive 
columns in a 96-well plate using an 8-channel manifold aspirator and replaced 
with 100ul control media, using an 8-channel pipette. Media was then aspirated 
from two (or three) adjacent consecutive columns and replaced with 100ul 
100nM CLM media. Plates were immediately returned to a 37°C incubator and 
incubated for 15 minutes before removing. Media from all wells was aspirated 
and replaced with 150~14% formaldehyde in PBS. Plates were then allowed to 
sit at room temperature, without shaking for 20 minutes. 
p38, JNK (500mM NaCI): 
In order to evaluate primary antibodies with specificity for active forms of 
p38 and JNK, cells were treated with 500mM NaCl in total media or with control 
media and incubated at 37°C for 30 minutes before fixation with 4% 
formaldehyde in PBS. Briefly, 5M NaCl stock in H20 was diluted 10-fold in total 
media for a final treatment concentration of 500mM NaCI. Control media 
consisted of total media. Media was aspirated from two (or three) consecutive 
columns in a 96-well plate using an 8-channel manifold aspirator and replaced 
with 100ul control media, using an 8-channel pipette. Media was then aspirated 
from three adjacent consecutive columns and replaced with 100ul 500mM NaCl 
media. Plates were immediately returned to a 37°C incubator and incubated for 
30 minutes before removing. Media from all wells was aspirated and replaced 
with 150~14% formaldehyde in PBS. Plates were then allowed to sit at room 
temperature, without shaking for 20 minutes. 
p53 (1 0pM DOX): 
In order to evaluate primary antibodies with specificity for one active form 
of p53, cells were treated with 10uM doxorubicin (DOX) in total media or with 
control media and incubated at 37°C for 12-14hrs before fixation with 4% 
formaldehyde in PBS. Briefly, 10mM doxorubicin stock in HZ0 was diluted 1000- 
fold in total media for a final treatment concentration of 10uM doxorubicin. 
Control media consisted of total media. Media was aspirated from two (or three) 
consecutive columns in a 96-well plate using an 8-channel manifold aspirator and 
replaced with 100ul control media, using an 8-channel pipette. Media was then 
aspirated from three adjacent consecutive columns and replaced with 100ul 
10uM doxorubicin media. Plates were immediately returned to a 37°C incubator 
and incubated for 12-14 hours before removing. Media from all wells was 
aspirated and replaced with 150~14% formaldehyde in PBS. Plates were then 
allowed to sit at room temperature, without shaking for 20 minutes. 
ERK (100nM PMA): 
In order to evaluate primary antibodies with specificity for the active form 
of ERK, cells were serum-starved over-night in DMEIHEP media + 0.1% FBS + 
1 % penicillinlstreptomycin + 1 % glutamine. They were then treated with 100nM 
PMA in total media or with control media and incubated at 37°C for 10 minutes 
before fixation with 4% formaldehyde in PBS. Briefly, 8.1 mM PMA stock in H20 
was diluted 81,000-fold in total media for a final treatment concentration of 
100nM PMA. Control media consisted of total media. Media was aspirated from 
two (or three) consecutive columns in a 96-well plate using an &channel 
manifold aspirator and replaced with 100ul control media, using an &channel 
pipette. Media was then aspirated from three adjacent consecutive columns and 
replaced with 100ul 100nM PMA media. Plates were immediately returned to a 
37°C incubator and incubated for 10 minutes before removing. Media from all 
wells was aspirated and replaced with 150~14% formaldehyde in PBS. Plates 
were then allowed to sit at room temperature, without shaking for 20 minutes. 
Immuno-staining and visualization was done as described in section VI 
(In-Cell Western Staining). 
111. Time-course cellular signaling experiments 
In order to investigate the time-dependent cellular signaling following CLM 
treatment, the following protocol was used. 
Cell culture conditions for monitoring cellular signaling following CLM 
treatment (Fig. 5): 
Tissue culture treated 96-well plates were seeded with U20S cells at 6,000 cells 
per well in 200ul total volume of DMElHEP media supplemented with 10% FBS, 
1 % penicillin/streptomycin, and 1 % glutamine (total media). Side edge wells 
were not seeded with cells but received the same total volume of media as other 
wells. Top and bottom edge wells were seeded as described. Wells were 
covered immediately with low-evaporation membranes in addition to plate tops 
and incubated overnight at 37°C. 
--Treatment and fixation- 
** We found that it was important that cells not be incubated for long periods with 
media containing CLM. Therefore, treatment of cells with CLM media was limited 
to a 15 minute period, at which point CLM media was replaced with fresh total 
media. 
0 time-points: 
0 time points correspond to no treatment. Briefly, media from all wells was 
aspirated and replaced with 150~14% formaldehyde in PBS. Plates were then 
allowed to sit at room temperature, without shaking for 20 minutes. 4% 
formaldehyde was then manually aspirated with an 8channel pipette and 
replaced with 150ul PBS. 
5 and 75 minute time-points: 
Cells were treated with 50nM CLM in total media, 5nM CLM in total media 
or with control media. Plates were then returned to a 37°C incubator for 5 and 15 
minute incubation times. Twenty seconds before each time-point, corresponding 
time-point plates were removed from incubator. Media from all wells was 
aspirated and replaced with 150~14% formaldehyde in PBS. Plates were then 
allowed to sit at room temperature, without shaking for 20 minutes. 4% 
formaldehyde was then manually aspirated with an 8-channel pipette and 
replaced with 150ul PBS. Treatment media was not replaced with fresh total 
media before fixation for these time-point plates. 
24h-30min time-points: 
Plates were removed, treated and returned to a 37°C incubator in waves 
consisting of 3 plates each, beginning with latest time-point plates and excluding 
time-point plates below 30 minutes (Time-point plates from 24 hours to 30 
minutes included). Cells were treated with 50nM CLM in total media, 5nM CLM 
in total media or with control media and incubated at 37°C for 15 minutes before 
replacement of treatment media with fresh total media in all wells, return to a 
37°C incubator for the remainder of the incubation time set for each time-point 
plate, and fixation with 4% formaldehyde in PBS at the end of that incubation 
time. Briefly, 50uM CLM stock or 5uM CLM stock in MeOH was diluted 1000-fold 
in total media for final treatment concentrations of 50nM or 5nM CLM. Control 
media consisted of an equivalent volume of 100% MeOH diluted in total media. 
Media was aspirated from four consecutive columns (Columns 2-5) on each of 
three 96-well plates using an &channel manifold aspirator and replaced with 
100ul control media, using an Schannel pipette. Media was then aspirated from 
three adjacent consecutive columns (Columns 6-8) on each of the three 96-well 
plates and replaced with 100ul 5nM CLM media. Media was then aspirated from 
three adjacent consecutive columns (Columns 9-1 1) on each of the three 96-well 
plates and replaced with 100ul 50nM CLM media. Plates were immediately 
returned to a 37°C incubator and incubated in treatment media for 15 minutes. 
Treated plates were then removed in the same order, one wave at a time. 
Treatment media was aspirated from all wells in one plate in a wave at a time, 
beginning with latest time-point plates, and replaced with 200ul fresh total media. 
Plates were immediately returned to a 37°C incubator for the incubation time 
remaining for each time-point. 
Twenty seconds before each time-point, corresponding time-point plates 
were removed from incubator. Media from all wells was aspirated and replaced 
with 150~14% formaldehyde in PBS. Plates were then allowed to sit at room 
temperature, without shaking for 20 minutes. 4% formaldehyde was then 
manually aspirated with an &channel pipette and replaced with 150ul PBS. 
Immuno-staining and visualization was done as described in section VI 
(In-Cell Western Staining). 
IV. Time-course cellular response experiments 
In order to investigate the time-dependent cellular response to CLM 
treatment, the following protocol was used. 
Cell culture conditions for monitoring cellular response following CL M treatment: 
10cm plates were seeded with U20S cells at 1.3 x 1 OA6 cells per plate in 
10ml total media and allowed to incubate overnight at 37°C prior to experiments. 
--Treatment and fixation- 
Previously seeded 10 cm plates were removed, treated with 50nM CLM in 
total media, 5nM CLM in total media or control media and returned to a 37°C 
incubator for 15 minutes. Plates were then removed and treatment media was 
replaced with 9ml fresh total media and returned to a 37°C incubator for the 
remaining incubation time set for each time-point. Treatment and replacement of 
treatment media with fresh total media was done in waves consisting of 6 plates 
each, beginning with plates to be collected at the latest time point. Each wave 
consisted of all plates to be collected at one of the three response time points: 
12, 24 and 48 hours. 50nM and 5nM CLM treatment media and control media 
was made as described for time-course treatment of 96-well plates. Briefly, for 
each wave, six 10 cm plates were removed from 37°C incubator. Media was 
aspirated from two plates and replaced with 5ml of 50nM CLM media. Media 
was aspirated from two more plates and replaced with 5ml of 5nM CLM media. 
Media was aspirated from the final two plates in the wave and replaced with 5ml 
of control media. Plates were immediately returned to a 37°C incubator for 15 
minutes. Plates from that wave were then removed. Media from those treated 
with 50nM CLM was aspirated and replaced with 9ml fresh total media. Media 
from those treated with 5nM CLM was aspirated and replaced with 9ml fresh total 
media. Finally, media from those treated with control media was aspirated and 
replaced with 9ml fresh total media. Plates were then returned to a 37°C 
incubator for the remaining incubation time set for that time-point. 
Twenty seconds before each time-point all six plates to be collected were 
removed from 37°C incubator. Beginning with those treated with 50nM CLM 
media, media was removed from two like-treated plates and reserved in pre- 
labeled 15ml falcon tubes. Plates were then rinsed with 2ml PBS. PBS was 
removed and reserved in same pre-labeled 15ml tubes, then replaced with 1.5ml 
trypsin + 0.2%EDTA. Plates treated with 5nM CLM media and control media 
were treated in a like manner. All plates were then returned to a 37°C incubator 
for 2 minutes to allow for cell detachment, then removed. Beginning with those 
plates treated with 50nM CLM media, 10ml of reserved media from the 
corresponding pre-labeled 15ml tube was added to quench trypsin and 
completely detach cells. Media was pipetted up and down a couple of times to 
clear the whole plate and then returned to the corresponding 15ml falcon tube. 
Plates treated with 5nM CLM and control media were treated in a like manner. 
All 15ml tubes were spun at 1000g for 5 minutes and the supernatant was 
aspirated. Cell pellets were resuspended in 400~14% formaldehyde in PBS, 
transferred to pre-labeled I ml eppendorf tubes and allowed to sit at room 
temperature for 10-15 minutes. Tubes were spun 2 minutes at 4000rpm (all 
subsequent spins are at 4000rpm for 2 minutes, through staining procedure), 
supernatant was removed and cells were resuspended in I ml PBS. Tubes were 
spun, supernatant was removed and cells were resuspended in 400ul100% 
MeOH. Tubes were stored at -20°C until staining for FACS analysis (cells can be 
stored for at least one week). 
Immuno-staining and visualization was done as described in section VII (FACS 
Staining). 
V. Positive control experiments (time course): positive controls used for 
normalization of time course experiments 
In each experiment, it was necessary to establish positive controls for 
each of the signals measured for normalization purposes. 
Treatment media and control media are all as described in Treatment procedure 
for validation experiments (section I I). 
ATM, CHK2, H2AX (Fig. 6): 
Media from 5 consecutive columns (Columns 2-6) was aspirated and in 
only three rows (Rows 3-5) was replaced with 100ul control media using a one- 
channel pipette. Media from 5 adjacent consecutive columns (Columns 7-1 1 ) 
was aspirated and in only three rows (Rows 3-5) was replaced with 100ul 100nM 
CLM in total media. The plate was immediately returned to a 37°C incubator and 
incubated for 15 minutes before removing. Media from all wells was aspirated 
and replaced with 150~14% formaldehyde in PBS. The plate was then allowed 
to sit at room temperature, without shaking for 20 minutes. 4% formaldehyde 
was then manually aspirated with an &channel pipette and replaced with 150ul 
PBS. 
p38, JNK (Fig. 7): 
Media from 5 consecutive columns (Columns 2-6) was aspirated and in 
only two rows (Rows 3-4) was replaced with 100ul control media using a one- 
channel pipette. Media from 5 adjacent consecutive columns (Columns 7-1 1) 
was aspirated and in only two rows (Rows 3-4) was replaced with 100ul 500mM 
NaCl in total media. The plate was immediately returned to a 37°C incubator and 
incubated for 30 minutes before removing. Media from all wells was aspirated 
and replaced with 150~14% formaldehyde in PBS. The plate was then allowed 
to sit at room temperature, without shaking for 20 minutes. 4% formaldehyde 
was then manually aspirated with an &channel pipette and replaced with 150ul 
. PBS. 
p53, ERK (Fig. 8): 
Media from 5 consecutive columns (Columns 2-6) was aspirated and in 
only one row (Row 3) was replaced with 100ul control media using a one-channel 
pipette. In one more row (Row 4) aspirated media was replaced with DMEIHEP 
+ 0.1 % FBS + 1 % penicillinlstreptomycin + 1 % glutamine (serum-starvation 
media). Media from 5 adjacent consecutive columns (Columns 7-1 1) was 
aspirated and in only one row (Row 3) was replaced with 100ul 10uM doxorubicin 
in total media. In one more row (Row 4) aspirated media was replaced with 
DMElHEP + 0.1 % FBS + 1 % penicillinlstreptomycin + 1 % glutamine (serum- 
starvation media). The plate was immediately returned to a 37°C incubator and 
incubated for 12 hours (over-night) before removing. Media from Row 4, 
Columns 7-1 1 was aspirated and replaced with 100ul of 100nM PMA. The plate 
was returned to a 37°C incubator and incubated for 10 minutes before removing. 
Media from all wells was aspirated and replaced with 150~14% formaldehyde in 
PBS. The plate was then allowed to sit at room temperature, without shaking for 
20 minutes. 4% formaldehyde was then manually aspirated with an &channel 
pipette and replaced with 150ul PBS. 
Immuno-staining and visualization was done as described in section VI 
(In-Cell Western Staining). 
Vl. In-cell Western (ICW) Staining 
For plates during time-courses: 4% formaldehyde was replaced with 
200ul PBS and allowed to remain in PBS without shaking until at least 4 plates 
had been fixed and it was convenient to begin the triton permeabilization (usually 
after the 4 hour time-point has been collected). PBS was then aspirated and 
replaced with the first of five triton permeabilization solution changes (1 50ul 0.1 % 
Triton in PBS). Remaining procedure is as described below. 
For In-cell Western staining, 4% formaldehyde was manually aspirated 
from all wells with an 8-channel pipette and replaced with 150ul 0.1 % Triton in 
PBS (triton permeabilization). All subsequent aspirations were done using an 8- 
channel manifold aspirator. Plates were gently shaken on a nutator for 5 
minutes. Triton permeabilization solution was aspirated, replaced with 150ul 
fresh triton permeabilization solution and gently shaken for 5 minutes. Triton 
permeabilization solution changes were repeated for a total of 5 changes. Final 
triton permeabilization solution change was aspirated, replaced with 150ul 
Odyssey Blocking Buffer and gently shaken at room temperature for 1.5 hours. 
Odyssey Blocking Buffer was aspirated, replaced with 50ul primary antibody 
diluted in Odyssey Blocking Buffer, gently shaken at room temperature for 1 hour 
and then placed at 4°C overnight without shaking. 
Primary anti body solution was aspirated, replaced with 1 50ul 0.1 % Tween in 
PBS (tween wash) and gently shaken at room temperature for 5 minutes. Tween 
wash was aspirated, replaced with 150ul fresh tween wash and gently shaken for 
5 minutes. Tween washes were repeated for a total of 4 washes. Final tween 
wash was aspirated and replaced with 50ul secondary antibody solution 
(secondary antibody (1 :500 dilution)+ Topro-3 DNA stain (1 :2500 dilution) diluted 
in Odyssey Blocking Buffer + 0.5% Tween). Plates were covered to protect from 
light and gently shaken at room temperature for 1 hour. Secondary antibody 
solution was aspirated, replaced with 150ul 0.1 % Tween in PBS (tween wash) 
and gently shaken at room temperature for 5 minutes. Tween wash was 
aspirated, replaced with 150ul fresh tween wash and gently shaken for 5 
minutes. Tween washes were repeated for a total of 4 washes. Final tween 
wash was aspirated thoroughly. Plates were tapped upside down on an 
absorbent surface to remove any remaining moisture in the wells, covered to 
protect from light and placed at 4C until scanned. 
IC W visualization and analysis: 
Plates were scanned on an Odyssey Infrared Scanner and analyzed using 
Odyssey software. 
V//. FACS Staining 
In order to assay for apoptosis and cell cycle profile of cell populations 
from the same biological samples, the following protocol was used. Cells in 
400ul 100% MeOH were resuspended by pipetting. 150ul from each sample was 
transferred to a pre-labelled I mi eppendorf tube and both aliquots were returned 
to -20°C until stained for FACS. The 250ul aliquot from each biological sample 
was stained for cleaved caspase 3 to assay for apoptosis, and the 150ul aliquot 
was stained for phospho-H3 and with propidium iodide to assay for cell cycle 
profile of the population, using the following respective protocols below. 
Cleaved Caspase-3 
Cells were repelleted by spinning at 4000rpm for 2 minutes in a 
microcentrifuge, and methanol was removed. Cells were resuspended in 400ul 
PBS + 0.1 % Tween (PBS-T). Cells were repelleted, PBS-T removed, and 100ul 
of primary antibody diluted in PBS-T + I  % BSA (PBS-TB) added. Cells were 
resuspended by pipetting up and down and incubated with primary antibody for 
one hour at room temperature. 400ul PBS-T was added and cells were 
repelleted, supernatant was removed, and cells were resuspended in another 
400ul PBS-T. Cells were repelleted, PBS-T wash was removed, resuspended in 
100ul of secondary antibody diluted in PBS-TB, and incubated at room 
temperature for one hour, covered to protect from light. 400ul PBS-T was added 
and cells were repelleted. Supernatant was removed, cells were resuspended in 
another 400ul PBS-T and repelleted again. PBS-T wash was removed and cells 
were resuspended in 400ul of PBS-TB. Tubes were left overnight at 4OC, 
covered to protect from light, then transferred into FACS tubes for immediate 
analysis. 
PI/P~osP~o-H~ 
Cells were repelleted by spinning at 4000rpm for 2 minutes in a 
microcentrifuge, methanol was removed, cells were resuspended in I ml PBS and 
repelleted. Cells were washed once more in PBS, repelleted and resuspend in 
400ul of PBS + 0.25% Triton for 15 minutes on ice. Cells were then repelleted 
and resuspended in 100ul PBS + 1 % BSA + 0.75~9 of anti-histone Hbphospho 
antibody and allowed to incubate for three hours at room temperature. Cells 
were then repelleted, resuspended in 400ul PBS + 1 % BSA then spun, 
resuspended in 100ul PBS + 1 % BSA + goat anti-rabbit IgG FlTC (Alexa fluor 
488) at 1.30 and allowed to incubate at room temperature for 30 minutes covered 
to protect from life. Cells were then spun, washed with I ml PBS and finally, 
resuspended in 600ul PBS + 50ug propidium iodide + Img RNase. Tubes were 
left overnight at 4OC, covered to protect from light, then transferred into FACS 
tubes for immediate analysis. 
FACS data was acquired using CellQuest software and analyzed using 
FlowJo software. 
Ill. Results and Discussion 
Results 
I. Experimental Design and Optimization of the In-Cell Western (ICW) assay 
The goal of our work is to quantitatively monitor the activity of proteins that 
contribute to the DNA damage response. To further this aim, In-Cell Western 
(ICW) assays were developed to monitor the phosphorylation of p38, ATM, 
H2AX, Chk2, p53, JNK and ERK. The In-Cell Western assay was chosen 
because it provides a straightforward means of collecting multiple time- 
dependent data points. The In-Cell Western assay involves 6 steps that are 
schematicized in Fig. 5: i) cells are seeded in 96-well plates, ii) cells are treated 
with an agent of choice, iii) cells are fixed, permeabilized and blocked, iv) cells 
are immuno-stained with antibodies raised against proteins andlor phospho- 
proteins of interest, v)primary antibodies are detected using an IR Dye800CW- 
conjugated secondary antibody and a measure of cell density is achieved by 
staining DNA with Topro-3 Iodide and vi) experiments are visualized using the 
LiCor Odyssey IR Scanner. 
Identification of antibodies suitable for monitoring DNA damage response 
protein phosphorylation by IC W 
An essential preliminary step in the development of ICW assays is the 
indentification of antibodies for the phopho-proteins of interest. The antibodies 
must fulfill the following requirements: (i) these antibodies must bind their target 
with a sufficient affinity so as to be detectable by ICW, (ii) the antibodies must be 
highly specific for their target, such that changes in signal detection can be taken 
to be reflective of changes in target levels, (iii) the antibodies must detect their 
target over a wide range of target protein concentration, and (iv) the detection 
signal must be proportional to the concentration of target protein over a sufficient 
range of protein concentration range. Antibody specificity is critical in the ICW 
assay format because detected proteins can not be separated by molecular 
weight as is the case in the traditional Western assay format. For each of the 
proteins of interest (p38, ATM, H2AX, Chk2, p53, JNK and ERK), multiple 
commercially available phospho-specific antibodies were screened for use in the 
ICW format. A single high-affinity antibody for each phospho-protein was 
identified for use in subsequent experiments. 
Commercial antibodies to be tested were chosen based upon Western 
blots provided by the manufacturer. Antibodies were chosen if they showed 
specificity for phosphorylated species over non-phosphorylated species, and a 
lack of background bands. The presence of background bands will decrease the 
ratio of signal between the background and the phosphoprotein of interest. The 
conditions under which proteins are detected in traditional and In-Cell Western 
protocols differ dramatically, and as such, the availability of target epitopes will 
likewise differ between these protocols. Therefore, it is not expected that 
an ti bodies with sufficient affinity and specificity may be rigorously identified 
through examination of traditional Westerns alone. For example, in the case of 
one phospho-specific Akt antibody tested (CST #4056), no background bands 
were detected in traditional Western format, but this antibody showed high 
background in ICW format (Fig. 9, A and B). Nonetheless, the pre-screening 
process generally gave valuable information as to the suitability of a given 
antibody for use in the ICW assay. 
Anti bodies possessing these characteristics were tested for their ability to 
bind their target antigens with sufficient affinity and specificity in the ICW format. 
For antibodies with sufficient affinity and specificity, the optimal antibody 
concentration for target detection was determined. 
Each antibody target was a protein modified by an activating 
phosphorylation or phosphorylations. In order to activate each protein of interest 
and induce these phosphorylations, cells were either treated or not treated with 
an agent known to lead to the modification of each of the respective proteins of 
interest (activating treatment). Following treatment and fixation, cells were 
immuno-stained in the In-cell Western format, with primary antibody dilutions of 
1 :50, 1 : 100, 1 250, 1 :500, 1 : 1000, 1 :ZOO0 and 1 :5000 (See Materials and 
Methods and Fig. 3 for a detailed explanation of Antibody dilution experiments). 
Sufficiency of specificity and affinity of each antibody for its target was 
determined by comparing the signal detected under treated (signal) and non- 
treated (background) conditions. The optimal antibody concentration was 
determined for those antibodies whose signal:background ratio was high. The 
optimal antibody concentration for each antibody was the concentration at which 
the signakbackground ratio was maximized. 
Determination of Dynamic Range and Linearity 
Cell number dilution experiments were performed with antibodies for 
which the optimal antibody concentration had been determined. The goals of 
these experiments were to determine if the antibodies yield a detection signal 
over a sufficiently wide range of target protein concentration and to show that the 
signal is directly proportional to the concentration of target protein over a 
sufficiently wide range of target protein concentration. 
In order to vary levels of protein concentration in the wells, cell density in 
the wells was varied. Cells were seeded at 10,000, 8,000, 6,000,4,000, 2,000 
and 0 cells per well (See Materials and Methods and Fig. 4 for a detailed 
explanation of Cell number dilution experiments). Differentially seeded wells 
were treated or not treated as in the antibody dilution experiments. 
Antibodies were considered to have a sufficient dynamic range if signal 
was detected from the lowest concentration of target protein assayed 
(corresponding to 2,000 cells plated per well and treated with activating 
treatment) and if signal (signal detected from cells treated with activating 
treatment) was always above background (signal detected from cells not treated 
with activating treatment). Antibodies were considered to have a sufficient linear 
range if the detected signal was linear with respect to target protein concentration 
from the concentration of target protein represented by 0 cells plated per well to 
the concentration of target protein represented by 6,000 cells plated per well. 
Phospho-A TM (Ser- 7987) 
ATM is phosphorylated on Serine 1981 following the induction of DNA 
double strand breaks, and this phosphorylation is a marker of ATM activation 
(Bakkenist and Kastan 2003). In the antibody validation experiments, ATM was 
activated by treating cells with 100nM calicheamicin for 15 minutes. 
Calicheamicin is a potent inducer of DNA double-strand breaks. 
The Upstate antibody had a good signakbackground ratio over the range 
of antibody concentrations assayed (Fig. IOA, pictured left panel, plotted A right 
panel). At an antibody dilution of 1:500 (corresponding to incubation of the wells 
with O.lug of antibody in 50ul total volume) signakbackground is maximized with 
signal more than 6-fold greater than background (Fig IOA, right panel, arrow). A 
1 :500 dilution was considered to be the optimal antibody dilution for this antibody, 
and all subsequent experiments were performed using this dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. IOB, pictured left panel, 
plotted right panel). Signal detected was linear with respect to target protein 
concentration, from the concentration of target protein represented by 0 cells 
plated per well, to the concentration of target protein represented by 8,000 cells 
plated per well (Fig. 1 OC, right panel). We considered that this antibody has 
sufficient dynamic and linear range to yield reliable, quantitative data that is 
directly reflective of levels of phospho-ATM. Above some protein concentration 
represented by 8,000 cells plated per well, antibody bound and detected was no 
longer linear and entered a plateau phase. Above this protein concentration, the 
antibody capture and detection step are unlikely to linearly report phospho- 
protein abundance in the wells. 
Chk2 is phosphorylated on Threonine 68 following the induction of DNA 
double strand breaks, and this phosphorylation is a marker of Chk2 activation 
(Matsuoka, Rotman et al. 2000; Melchionna, Chen et al. 2000). Chk2 was 
activated in antibody validation experiments by treating cells with 100nM CLM for 
15 minutes. 
The Cell Signaling Technologies antibody had a very good 
signakbackground ratio over almost the whole range of antibody concentrations 
assayed and signa1:background continued to increase with increasing antibody 
concentration (Fig. 1 IA,  pictured left panel, plotted A right panel). At an antibody 
dilution of 1:250 (corresponding to incubation of wells with 0.02ug of antibody in 
50ul total volume) signakbackground is very high, with signal more than 10-fold 
greater than background (Fig 1 IA,  right panel, arrow). Higher concentration of 
antibody (although somewhat further increasing the signakbackground ratio) was 
considered unnecessary. A 1:250 dilution was considered to be the optimal 
antibody dilution for this antibody, and all subsequent experiments were 
performed using this dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. 11 B, pictured left panel, 
plotted right panel). Signal detected was linear with respect to target protein 
concentration, from the concentration of target protein represented by 0 cells 
plated per well, to the concentration of target protein represented by 6,000 cells 
plated per well (Fig. 11 C, right panel). This antibody has sufficient dynamic and 
linear range to yield reliable, quantitative data that is directly reflective of levels of 
phospho-Chk2. Above a protein concentration represented by 6,000 cells plated 
per well, antibody bound and detected was no longer linear and entered a 
plateau phase. Above this protein concentration, the antibody capture and 
detection step is unlikely to linearly report phospho-protein abundance in the 
wells. 
Phospho-H2AX (Ser- 739) 
H2AX is phosphorylated on Serine 139 following the induction of DNA 
double strand breaks, and this phosphorylation is a marker of activation (Burma, 
Chen et al. 2001 ; Mochan, Venere et al. 2004; Friesner, Liu et al. 2005). H2AX 
was activated in Antibody dilution experiments by treating cells with 100nM CLM 
for 15 minutes. 
The Cell Signalling Technologies antibody had a good signakbackground 
ratio over a large range of antibody concentrations assayed and 
signakbackground always increased with increasing antibody concentration (Fig. 
12A, pictured left panel, plotted A right panel). At an antibody dilution of 1 :200 
(corresponding to incubation of wells with 0.025~9 of antibody in 50ul total 
volume) signakbackground is very high, with signal more than 10-fold greater 
than background (Fig 12A, right panel, arrow). Higher concentration of antibody 
(although further increasing the signal: background ratio) was considered 
unnecessary. A 1 :200 dilution was considered to be the optimal antibody dilution 
for this antibody, and all subsequent experiments were performed using this 
dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. 128, pictured left panel, 
plotted right panel). Signal detected was linear with respect to target protein 
concentration, from the concentration of target protein represented by 0 cells 
plated per well, to the concentration of target protein represented by 6,000 cells 
plated per well (Fig. 12C, right panel). This antibody has sufficient dynamic and 
linear range to yield reliable, quantitative data that is directly reflective of levels of 
phospho-H2AX. Above a protein concentration represented by 6,000 cells plated 
per well, antibody bound and detected was no longer linear and entered a 
plateau phase. Above this protein concentration, the antibody capture and 
detection step is unlikely to linearly report phospho-protein abundance in the 
wells. 
Phospho-JNK (Thr- 7 83/Tyr- 785) 
JNK is dually phosphorylated on Threonine 183 and Tyrosine 185 
following various cellular stresses, including osmotic stress. Phosphorylation is a 
marker of JNK activation (Deacon and Blank 1997; Yung, Dolginov et al. 1997). 
JNK was activated in Antibody dilution experiments by treating cells with 500mM 
NaCl for 30 minutes. 
The Cell Signaling Technologies antibody exhibits a lower absolute signal 
than Phospho-ATM, Chk2 or H2AX antibodies. However, it had acceptable 
signal:background ratio over almost the whole range of antibody concentrations 
assayed (Fig. 13A, pictured left panel, plotted A right panel). At an antibody 
dilution of 1 : I  00 (corresponding to incubation of wells with 0.05ug of antibody in 
50ul total volume) signal to background ratio is close to its consistent maximum 
with signal more than 3-fold greater than background (Fig 13A, right panel, 
arrow). At this dilution, absolute signal was significantly higher than that detected 
using lower antibody concentrations. A 1 : I  00 dilution was considered to be the 
optimal antibody dilution for this antibody, and all subsequent experiments were 
performed using this dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. 136, pictured left panel, 
plotted right panel). Signal detected was linear with respect to target protein 
concentration, from the concentration of target protein represented by 0 cells 
plated per well, to the concentration of target protein represented by 6,000 cells 
plated per well (Fig. 13C, right panel). This antibody has sufficient dynamic and 
linear range to yield reliable, quantitative data that directly reports levels of 
phospho-JNK. Above a protein concentration represented by 6,000 cells plated 
per well, the amount of antibody bound and detected was no longer linear and 
entered a plateau phase. Above this protein concentration, the antibody capture 
and detection step cannot be relied upon to linearly reflect phospho-protein 
abundance in the wells. 
Phospho-p38 (Threonine 780/Tyrosine 7 82) 
p38 is dually phosphorylated on Threonine 180 and Tyrosine 182 following 
various cellular stresses, such as osmotic stress, and this phosphorylation is a 
marker of p38 activation (Deacon and Blank 1997; Yung, Dolginov et al. 1997). 
p38 was activated in Antibody dilution experiments by treating cells with 500mM 
NaCl for 30 minutes. 
The Cell Signaling Technologies phospho-p38 antibody had a lower 
absolute signal than phospho-ATM, phospho-Chk2 or phospho-H2AX antibodies. 
However, it had acceptable signakbackground ratio over a limited range of 
antibody concentrations assayed (Fig. 14A, pictured left panel, plotted right 
panel). At an antibody dilution of 1 : I  00 (corresponding to incubation of wells with 
0.05ug of antibody in 50ul total volume) signakbackground is maximum with 
signal more than 3-fold greater than background (Fig 14A, right panel, arrow). A 
1 :I 00 dilution was considered to be the optimal antibody dilution for this antibody, 
and all subsequent experiments were performed using this dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. 14B, pictured left panel, 
plotted right panel). Signal detected was linear with respect to target protein 
concentration, from the concentration of target protein represented by 0 cells 
plated per well, to the concentration of target protein represented by 8,000 cells 
plated per well (Fig. 14C, right panel). This antibody has sufficient dynamic and 
linear range to yield reliable, quantitative data that is directly reflective of levels of 
phospho-JNK. Above a protein concentration represented by 8,000 cells plated 
per well, the amount of antibody bound and detected was no longer linear and 
entered a plateau phase. Above this protein concentration, the antibody capture 
and detection step can not be relied upon to linearly reflect phospho-protein 
abundance in the wells. 
Phospho-ERK (Threonine 7 8nyrosine 784) 
ERK is dually phosphorylated on Threonine 182 and Tyrosine 184 
following stimulation with various cytokines and growth factors. This 
phosphorylation is a marker of ERK activation (Deacon and Blank 1997; Yung, 
Dolginov et al. 1997; Orton, Sturm et al. 2005). The activating treatment used in 
validating phopho-ERK antibodies is overnight serum starvation followed by 
treatment of cells with 100nM phorbol 1 2-myristate 13-acetate (PMA, a 
diacylg lycerol (DAG) analog) for 5 minutes. 
The Cell Signaling Technologies antibody had a lower absolute signal 
than Phospho-ATM, Chk2 or H2AX antibodies. However, it had acceptable 
signakbackground ratio over a limited range of antibody concentrations assayed 
(Fig. 15A, pictured left panel, plotted right panel). At an antibody dilution of 1 :I00 
(corresponding to incubation of wells with 0.05ug of antibody in 50ul total 
volume) signakbackground is close to its maximum with signal more than 3-fold 
greater than background (Fig 15A, right panel, arrow). A 1 :I00 dilution was 
considered to be the optimal antibody dilution for this antibody, and all 
subsequent experiments were performed using this dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. 158, pictured left panel, 
plotted right panel). Signal detected was linear with respect to target protein 
concentration, from the concentration of target protein represented by 0 cells 
plated per well, to the concentration of target protein represented by 6,000 cells 
plated per well (Fig. 1 5C, right panel). This antibody has sufficient dynamic and 
linear range to yield reliable, quantitative data that is directly reflective of levels of 
phospho-ERK. Above a protein concentration represented by 6,000 cells plated 
per well, antibody bound and detected was no longer linear and entered an 
exponential rise phase. Above this protein concentration, the antibody capture 
and detection step can not be relied upon to linearly reflect phospho-protein 
abundance in the wells. 
p53 (Serine 15) 
p53 is phosphorylated on Serine 15 following induction of general DNA 
damage. This phosphorylation is a marker of p53 activation (Caspari 2000; 
Appella and Anderson 2001 ). The activating treatment used in validation 
experiments for the phospho-p53 antibody is treatment of cells with 10uM 
doxorubicin (DOX) for 12 hours. 
The Cell Signaling Technologies antibody had a lower absolute signal 
than phospho-ATM, phospho-Chk2 or phospho-H2AX antibodies. Treatment 
with DOX, in addition to activating p53, is pro-apoptotic and leads to apoptosis in 
some percentage of treated cells. U20S cells become non-adherent when they 
are apoptotic, and it is difficult to retain these cells for staining in the In-cell 
Western format. As a result, there are fewer cells available for staining in the 
treated populations than in the untreated populations and so the detected signal 
must be normalized based on this reduced number of cells. In order to 
accommodate this requirement, treated and untreated cells were stained 
concurrently with a DNA stain (for cell number normalization) and 
immunologically for phospho-p53 (Fig. 16A and B, left and middle panels). In 
wells containing treated cells, as opposed to in wells containing untreated cells, 
significantly fewer cells remained following fixation and staining (compare Fig. 
16A, middle panel, (-) and (+) and Fig. 166, middle panel, (-) and (+)). Following 
normalization of signal to DNA present, it was found that this antibody had 
acceptable signakbackground ratio over a limited range of antibody 
concentrations assayed (Fig. 16A, pictured left and center panel, plotted right 
panel). At an antibody dilution of 1 :500 (corresponding to incubation of wells with 
O.Olug of antibody in 50ul total volume) signakbackground is maximum with 
signal nearly 10-fold greater than background (Fig 16A, right panel, arrow). A 
1500 dilution was the optimal antibody dilution for this antibody, and all 
subsequent experiments were performed using this dilution. 
Using this optimal antibody dilution, signal was detected at the lowest 
concentration of target protein assayed (corresponding to 2,000 cells plated per 
well) and signal was always above background (Fig. 166, pictured left and center 
panel, plotted right panel). Signal detected was linear with respect to target 
protein concentration, from the concentration of target protein represented by 0 
cells plated per well, to the concentration of target protein represented by 6,000 
cells plated per well (Fig. 16C, right panel). This antibody has sufficient dynamic 
and linear range to yield reliable, quantitative data that is directly reflective of 
levels of phosphorylation of p53. Above a protein concentration represented by 
6,000 cells plated per well, antibody bound and detected was no longer linear 
and entered a plateau phase. Above this protein concentration, we considered 
that the antibody capture and detection step can not be relied upon to linearly 
reflect phospho-protein abundance in the wells. 
Antibodies incompatible with the IC W format 
Antibodies tested but not selected based on failure of one or more of these 
conditions are listed in Table 2 
Table 2. 
Target protein 
Phospho-JNK 
Phospho-ATM, Ser-1981 
Phospho-Akt 
Phospho-ERK 
Phospho-p38 
Phospho-MK2 
Phospho-MK2 
Phospho-hsp27 
Phospho-p53, Ser-I 5 
Phospho-p53, Ser-20 
Phospho-p53, Ser-20 
p53, total 
Manufacturer 
Biosource 
Rockland 
CST #4056 
CST #4376 
CST #92 1 6 
CST 
CST 
CST 
Calbiochem 
Calbiochem 
CST 
CST 
Mode of failure 
High background 
Low signal 
High background 
High background 
High background 
High background 
High background 
High background 
High background 
Low signal 
High background 
High background 
Experimental Considerations 
As was the case for the activating treatment used in the validation of the 
phospho-p53 antibody, many treatments will lead to apoptosis in some 
percentage of the population. Because of this, it is necessary to normalize the 
signal to the cell number present. Therefore, in all subsequent experiments, In- 
cell Western staining consisted of concurrent staining with DNA stain (for cell 
number normalization) and immunological staining for target protein. 
For each antibody validated for use in subsequent experiments, the 
amount of antibody bound was not linear above some protein concentration in 
the wells. In this non-linear range, the antibody capture and detection step can 
not be relied upon to linearly reflect phospho-protein abundance. The threshold 
for non-linear antibody binding varied among antibodies, but was never lower 
than a protein concentration represented by 6,000 cells plated per well. 
Therefore, in all subsequent experiments, cells were seeded at 6,000 cells per 
well in order to ensure linearity of detection and to maintain a parallel and 
consistent seeding step. 
Experiments were highly reproducible and in tra-assay error was almost 
always S 10%. As such, the high throughput ICW assays are capable of 
providing reproducible, quantitative measurements of levels of target proteins 
modified with activating phosphorylations. 
11. Analysis of the calicheamicin-induced DSB response 
U20S cells are a p53 wild type human osteosarcoma cell line that die in 
response to ionizing radiation (IR)-induced double strand breaks (DSB). We 
determined that U20S cells also die in response to DSB induced by the enidyne 
antibiotic agent, calicheamicin (CLM), and that the extent of this response is 
highly dose-dependent (Fig. 20). We also determined that U20S cells exhibit 
severe cell cycle phenotypes in response to CLM-induced DSB and that the cell- 
cycle phenotype exhibited varies dramatically in a dose-dependent manner (Fig. 
21, 22). Based on these results, we set out to investigate the differential 
signaling dynamics, following treatment with various doses of CLM, which might 
be involved in mediating these dramatic dose-dependent phenotypic differences. 
U20S cells were treated with OnM, 5nM or 50nM CLM in triplicate well 
samples per experiment, over two separate experiments (Fig. 5), and 
formaldehyde fixed for signal analysis at 12 time points over 27 hours. There is a 
very fast (on the order of minutes) response to the induction of DSB in the cell 
and there is an early-phase of activity in which protein kinetics are expected to be 
quite rapid; this fast response is followed by a later, longer and more sustained 
period of response and repair (Appella and Anderson 2001 ; Celeste, Fernandez- 
Capetillo et al. 2003; Kastan and Bartek 2004). It has also been observed that 
repair of CLM-induced DSB follows biphasic kinetics, consisting of an early fast 
repair period (completed within the two hours following lesion induction) and a 
late, long repair period that is sustained through a 24 hour period following lesion 
induction (Elmroth, Nygren et al. 2003). Based upon this knowledge, time points 
were most densely sampled in the first 2 hours (Fig. 17, left panels). Levels of 
activated ATM, Chk2, HZAX, JNK, p38, ERK and p53 were measured at these 
time-points, in triplicate, using the high-throughput ICW assays (Fig. 17, right 
panels). In order to compare the dose-dependent signaling differences, we 
performed a three way comparison for each target protein under 50nM, 5nM and 
OnM CLM treatment (Fig. 18). 
Response measurement time-points were collected in duplicate at three 
time-points over 48 hours (12, 24 and 48h). Cell death in the population was 
measured by FACS detection of cleaved caspase-3 (representative data shown 
in Fig. 19, quantified in Fig. 20) and by sub-GI PI incorporation (Fig. 22). Cell 
cycle profile in the population was also measured by FACS detection of relative 
PI incorporation (Fig. 21, 22). 
Cellular signaling 
Time-course of signaling 
All protein activation levels were normalized to their measured activation 
levels at time 0 (corresponding to no treatment, n = 9, triplicate samples on three 
separate plates). Fold activation at each time-point is reported with respect to 
this measured level of activation. Cells treated with OnM CLM served as a 
negative control in these experiments. 
Except in the case of ATM, following the negative control treatment of OnM 
CLM, protein activation levels never deviated from the no-treatment activation 
levels by more than +I- 60%, (Fig. 17A, right panel). ATM activation levels 
increased significantly from no-treatment activation levels following treatment 
with OnM CLM at late time-points. ATM activation levels jumped to 4.6 fold 
activation at 12 hours. This high activation level at 12 hours is followed by a dip 
to a 2.8 fold activation level at 16 hours, and climbs again to a 5.4 fold activation 
level at the latest time-point of 26.5 hours (Fig. 17A, right panel). 
Following treatment with 5nM CLM, protein activation levels of all proteins, 
except H2AX and ATM, remained low over the full time-course, never exceeding 
a 2-fold activation level (Fig. 178, right panel). H2AX activation levels peaked 
quickly, reaching a maximum activation of more than 8-fold at 30 minutes. This 
high activation level is not sustained and dropped quickly to just above 5-fold 
activation by 90 minutes (Fig. 178, left panel). H2AX activation levels decreased 
slowly over the rest of the time-course and returned to no-treatment levels by 
26.5 hours (Fig. 17B, right panel). ATM levels also peaked quickly, reaching a 
maximum activation of 3.8-fold activation at 30 minutes and remained at this 
level through 1 hour, before dropping to just above 2-fold activation levels by 90 
minutes (Fig. 17B, left panel). Activation levels of ATM rose again to just above 
3-fold by 2 hours and then decreased slowly to just above 2-fold activation levels 
by 8 hours (Fig. 178, right panel). By 12 hours, ATM's measured level of 
activation was nearly 5-fold. This activation level is similar to the activation levels 
found for ATM at this time following OnM CLM treatment. This high activation 
level for ATM persisted for the remainder of the time-course (through 26.5 hours) 
(Fig. 178, right panel). 
Following 50nM CLM treatment, protein activation levels of H2AX and 
ATM were again highly activated, but to an even larger extent than following 5nM 
CLM treatment. H2AX activation levels peaked at more than 12-fold at just 15 
minutes following treatment, dropped to 9-fold by 90 minutes, and recovered to 
another peak of 12.5-fold activation at 2 hours (Fig. 17C, left panel). Following 
this peak, H2AX activation levels decreased sharply to 7.6-fold by 6 hours, and 
rose once more to 9.5-fold, before decreasing slowly over the remainder of the 
time-course to just above 3-fold at 26.5 hours (Fig. 17C, right panel). Similar to 
its behavior following 5nM CLM treatment, ATM activation levels once again 
peaked by 30 minutes following 50nM CLM treatment, although this time at a 
much higher activation level of 7-fold (Fig. 17C, left panel). This activation level 
dropped slightly to 6-fold by 90 minutes, before recovering to another peak of 
activation of 7.4-fold by 2 hours (Fig. 17C, left panel). This peak was followed by 
a sharp decline in activation level to 4.7-fold by 6 hours and, as is seen in both 
the OnM and 5nM CLM treated populations, ATM activation levels once again 
rose to very high levels at 12 hours following treatment (6.9-fold) and remained 
high for the remainder of the time-course (Fig. 17C, right panel). 
In contrast to their lack of significant activation following 5nM CLM 
treatment, Chk2 and p38 are highly activated following 50nM CLM treatment 
(Fig. 18A, right panel, Fig. 18C, left panel). Chk2 activation levels increased to 
3.3-fold by 30 minutes following 50nM CLM treatment (Fig. 17C, left panel). This 
Chk2 activation level was maintained through 90 minutes. Activation levels 
increased to greater than 4-fold at 2 hours, and this activation level was 
maintained through 4 hours, at which point Chk2 activation levels decreased 
quickly to 2.6 fold at 6 hours and continued to decrease slowly for the remainder 
of the time-course. Chk2 activation levels reached as low as 1.5-fold at 26.5 
hours following treatment (Fig. 17C, right panel). The initial rise in p38 activation 
levels following 50nM CLM treatment was delayed with respect to the initial 
activation of H2AX, ATM, and Chk2 (Figure 17C, left panel). Activation levels of 
p38 rose quickly at 2 hours following 50nM CLM treatment and reached a peak 
activation level of 3.5-fold at 4 hours following treatment (Fig. 18C, left panel). 
Activation levels of p38 dropped quickly back to 1.6-fold by 6 hours and 
continued to slowly decline over the remainder of the time-course to 1.2-fold at 
26.5 hours (Fig. 17C, right panel). 
Similar to their behavior following 5nM CLM treatment, the remaining 
proteins, including p53, JNK and ERK remained at low levels of activation 
following 50nM CLM treatment, never exceeding a 2-fold activation level (Fig. 
18D and Fig. 18B and 18C, right panels, respectively). 
Dose-dependent signaling 
While H2AX and ATM are highly activated following both 5nM and 50nM 
CLM treatment, there is a significant dose-dependence in the extent of this 
activation. Both initial activation peaks and maximal activation peaks are 
dramatically higher following 50nM CLM treatment than following 5nM CLM 
treatment (Fig. 18A and 18B, left panels). The initial activation peak of H2AX 
following 5nM CLM treatment reaches 8.1-fold, while the initial activation peak 
following 50nM CLM treatment reaches 12.1-fold (Fig. 18B, left panel). The initial 
activation peak of ATM following 5nM CLM treatment reaches 3.8-fold, while the 
initial activation peak following 50nM CLM treatment reaches 7-fold (Fig. 18A, left 
panel). 
The trajectories of activation of both Chk2 and p38 following 5nM and 
50nM CLM treatment are clearly qualitatively, as well as quantitatively, different. 
Neither Chk2 nor p38 are significantly activated following treatment with 5nM 
CLM. However, both are significantly activated following treatment with 50nM 
CLM. Chk2 reaches a maximal activation level of 4.6-fold at 4 hours following 
treatment (Fig. 18A, right panel), while p38 reaches a maximal activation level of 
3.5-fold also 4 hours following treatment (Fig. 18C, left panel). 
Neither ERK nor JNK show any significant activation over the 26.5 hours 
following treatment with either 5nM or 50nM CLM. The activation level of these 
proteins following treatment with OnM, 5nM and 50nM CLM never exceeds 1.6- 
fold. Additionally, the trajectories of activation of ERK following treatment with 
OnM, 5nM and 50nM CLM, as well as those of JNK following treatment with 
OnM, 5nM and 50nM CLM, are virtually super-imposable (Fig. 188 and 18C, right 
panels). 
The activation level of p53 never exceeds 1.7-fold activation following 5nM 
or 50nM CLM treatment. However, while the trajectories of activation of p53 
following 5nM or 50nM CLM are virtually identical, these trajectories differ from 
that of p53 activation following treatment with OnM CLM (Fig. 18D). Maximal 
activation levels of p53 following both 5nM and 50nM CLM treatment are reached 
at 8 hours following treatment and correspond to 1.6- and I .7-fold activation 
respectively, while the activation level measured following OnM treatment 
remains flat at 1. 
Cellular response 
Microscopic analysis 
Cell populations were observed under a light microscope at 12, 24 and 48 
hours following treatment with no, low and high dose CLM. At 12 hours, 
following both 5 and 50nM treatment, cells morphology was large, flat, and 
spread out with large flat nuclei as compared to the control cells. In addition, 
while control populations had a large number of cells observably undergoing 
mitosis (twinned cells lifted up off the plate surface), in both treated populations 
there was no observable mitosis. 
After 24 hours, untreated populations had noticeably fewer observably 
mitotic cells than after 12 hours, which is to be expected as cells at this point are 
fairly confluent and somewhat contact inhibited. Cell populations treated with the 
low dose of CLM have no observable mitosis. Cell populations treated with the 
high dose of CLM display a very large number of cells observably in the mitotic 
state (twinned cells lifted up off the plate surface). 
After 48 hours, the untreated populations display virtually no observable 
mitosis (as previously discussed, this is due to contact inhibition, which is quite 
extensive at this point). Low dose-treated populations show a large number of 
cells observably in the mitotic state, and high dose-treated populations consist of 
nearly all floating or apoptotic cells, as assessed by nuclear blebbing (data not 
shown). 
Cell cycle profiles were determined at 12, 24 and 48 hours following 
treatment with no, low and high dose CLM by FACS based detection of relative 
propidium iodide (PI) incorporation. Figure 21 shows sample cell-cycle data from 
each of these time and treatment points. Figure 22 shows an average of cell- 
cycle data collected at each of these time and treatment points over four 
individual experiments (Fig. 21, 22). Cells treated with OnM CLM served as a 
negative control in this experiment. 
At 12 hours following treatment with OnM CLM, cell populations displayed 
population percentages in GI ,  S and G21M phases of 46+/-3%, la+/-0.6% and 23+/- 
1 % respectively (Fig. 22, top left). This population distribution is consistent with 
widely accepted distributions for normal cell populations of population 
percentages in GI ,  S and G2lM phases of 50%, 20% and 20% respectively. 
This population distribution is preserved at 24 hours following treatment in the 
OnM CLM treated population (Fig. 22, top middle). At 48 hours, the percentage 
of the population in G I  has increased (46+1-3% at 12 hours, 54+/-2% at 48 hours) 
and the percentage of the population in G2lM has decreased (23+/-1% at 12 
hours, 13+/-4% at 48 hours) (Fig. 22, top left and top right). These shifts in 
population percentages in cell populations treated with OnM CLM reflects an 
expected adjustment to slower population proliferation rates as cell density on 
the plate becomes very high. 
At 12 hours following treatment with 5nM CLM, cell populations displayed 
population percentages in GI,  S and G2lM phases of 30+1-2%, 27+/-2% and 34+/- 
2% respectively (Fig. 22, middle left) indicating an increase in the G2lM 
population over control population distributions, a possible increase in the S 
phase populations over control population distributions, and a decrease in G I  
population. At 24 hours following treatment with 5nM CLM, cell populations 
displayed population percentages in GI ,  S and G21M phases of 8+1-2%, 23+1-8% 
and 54+1-6% respectively (Fig. 22, center). This distribution is dramatically 
different from that displayed by control cell populations. It indicates a greatly 
increased G21M population (54+1-6% in 5nM-treated population, 19+1-4% in OnM 
treated population) and a nearly abolished G I  population (8+1-2% in 5nM-treated 
population, 48+1-4% in OnM-treated population) (Fig. 22, center and top middle). 
The S phase population, at 23+1-8% of the population, is consistent with control 
cell population distributions. At 48 hours following treatment with 5nM CLM, cell 
populations displayed population percentages in GI, S and G21M phases of 6+1- 
0.7%, 14+1-5% and 49+1-i % respectively (Fig. 22, middle right), indicating a 
decrease in the S phase population. Additionally, the population distribution 
includes a small sub-GI population of 5+1-o.I%, indicating a small amount of cell 
death, and a large aneuploid population of 26+1-7% (versus 14+1-5% in control 
populations; Fig. 22, top right). 
At 12 hours following treatment with 50nM CLM, cell populations displayed 
population percentages in GI ,  S and G21M phases of 39+1-3%, 24+1-1% and 28+1- 
3% respectively (Fig. 22, bottom left), indicating a decrease in the G I  population 
from control population distributions (46+1-3% in OnM-treated populations, Fig. 22, 
top left). At 24 hours following treatment with 50nM CLM, cell populations 
displayed population percentages in GI, S and G21M phases of 31 +I-3%, 24+1-I% 
and 31 +I-3% respectively (Fig. 22, bottom middle), indicating a further decrease in 
G I  population and an increase in the G2lM population over that that found in 
control cell populations (31 +I-3% in 50nM-treated, 19+1-4% in OnM-treated). At 48 
hours following treatment with 50nM CLM, cell populations displayed population 
percentages in GI, S and G2lM phases of 1 3+1-o.I%, lo+/-0.4% and 20+1-4% 
respectively (Fig. 22, bottom right), with a large sub-GI population of 45+1-8%, 
indicating a large amount of cell death. This distribution indicates a dramatic 
decrease in G I  and S phase populations, as well as a subsequent decrease in 
the G2lM population following the previous increase in this population above 
control levels observed at 24 hours following treatment (31 +I-4% at 24 hours, 20+1- 
4% at 48 hours, Fig. 22, bottom right and bottom middle). 
Apoptotic measurements 
Apoptosis in treated and untreated populations was measured by FACS 
detection cleaved caspase-3, an early apoptotic effector molecule. Apoptosis in 
populations treated with 5nM CLM was not found to be significantly elevated 
above levels in untreated populations at 24 or 48 hrs. Apoptosis in populations 
treated with 50nM CLM was found to be dramatically elevated above levels in 
untreated populations at 24 and 48 hours (>24% at 24 hours and >60% at 48 
hours). 
Discussion 
In-cell Western Assay 
Intra-assay variation 
A major component of this work was the validation of the In-cell Western 
as a technique for monitoring the phosphorylation state of proteins involved in 
DNA damage signaling. As such, it is pertinent to consider the shortcomings of 
this assay. 
Systematic error in quantifying protein activation levels from plate to plate 
in the ICW assay is a concern. The inclusion of both a positive and negative 
control for each protein activation level, on each plate in the time-course, would 
allow for very rigorous checks on such systematic error. This is not possible in 
the format of the ICW assay. However, the low level of deviation of protein 
activation data in the negative control-treated population (OnM CLM treatment) 
across all plates in the time-course (time-points: 5min to 26.5h) from the level of 
protein activation following no treatment (time-point: Omin, measured in triplicate 
on three separate plates), demonstrates that systematic error is not a 
confounding element in this data collection method (Fig. 17A). 
A TM: is intra-assay variation a fact or an artefact? 
We did observe a significant deviation of protein activation levels for ATM 
in the OnM CLM-treated population, from the level of protein activation following 
no treatment, at late time-points (12 hours and later) (Fig. 17A, right panel). This 
deviation is unexpected. It appears to be artefactual and raises questions as to 
the reliability of the phospho-ATM antibody used in these assays. 
The unexpected activation of ATM following treatment with OnM CLM is 
observed only at late time-points (compare Fig. 17A left panel and right panel), at 
which point, cell density is very high. It is known that many cell processes shift 
dramatically at high cell density and that protein activation levels, specifically of 
known tumor suppressors and cell-cycle regulators, differ from activation levels 
observed at low cell density (Kammouni, Ramakrishna et al. 2002; Bar, Cohen- 
Noyman et al. 2004; Uegaki, Kanamori et al. 2005). It is possible that the 
unexpected levels of measured ATM activation in this assay are not artefactual, 
and instead represent real changes in ATM activation that occur at high cell 
density. These findings require further investigation. 
Cellular Signaling 
The conclusions described below are based on In-cell Western data 
alone. All of these data would benefit by initial additional validation by 
quantitative western blot. 
As expected, ATM, H2AX and Chk2 were all highly activated immediately 
following treatment with high dose (50nM) CLM (Fig. 17, B and C, left panels). 
ATM and H2AX are both activated following low dose (5nM) CLM treatment, 
though not to the extent that they are activated following high dose treatment 
(Fig. 178). Unexpectedly, Chk2 is not highly activated following low dose 
treatment with CLM (Fig. 178, left and right panels). Following 5nM treatment, 
Chk2 shows only subtle quantitative differences in trajectory as compared to 
control (no treatment), with activation never exceeding 2-fold. It seems unlikely 
that Chk2 does not play a role in the DSB response following low dose CLM 
treatment as ATM is quite highly activated, and Chk2 is a well-established 
substrate of ATM (Matsuoka, Rotman et al. 2000; Zhou, Chaturvedi et al. 2000). 
Therefore it is possible that these subtle quantitative differences are critical for 
Chk2's role in low dose response. 
p38 was highly activated following high dose CLM treatment (Fig. 17C, 
right panel) although with largely different and far slower kinetics. As compared 
to ATM, H2AX and Chk2, which all reach an initial peak in activation by 30 
minutes following treatment with 50nM CLM, p38 reached a peak of 3.5-fold 
activation only by 4 hours following treatment (Fig. 18C, left panel). Additionally, 
p38 is not activated in response to low dose CLM (Fig. 17B). Taken together, 
these results suggest a role for p38 in DSB response that is related to longer 
term effector responses, rather than initial lesion sensing and immediate 
response. 
We did not observe a dramatic activation of p53 (Fig. 178 and C, right 
panels). Trajectories of activation for p53 in cells following 5nM and 50nM CLM 
treatment are nearly identical (Fig. 18D, left panel), despite the highly divergent 
cellular apoptotic response at these doses. 5nM CLM treatment elicited a very 
low level of apoptosis in treated cell populations (- 5% by 48 hours), and 50nM 
CLM treatment elicited a very strong apoptotic response in treated cell 
populations (>20% at 24 hours, >60% at 48 hours) (Fig. 20). Nearly identical 
trajectories of activation of p53 in cell populations following 5nM and 50nM CLM 
treatment, correspond to dramatically divergent apoptotic outcomes in these 
differentially treated populations. These observations are interesting in light of 
the well-established role of p53 in promoting apoptosis, and suggest the 
possibility of a p53-independent apoptotic response following CLM treatment. 
Indeed, other groups have found that CLM may induce apoptosis in a p53- 
independent manner (Prokop, Wrasidlo et al. 2003), consistent with data 
presented here. 
Trajectories of JNK and ERK activation following low or high dose CLM 
treatment are nearly super-imposable with control levels (Fig. 188 and C, right 
panels). This may imply that these signaling pathways are not highly utilized in 
the DSB response. It is possible that it is necessary to measure activation levels 
at time-points later than 27 hours following induction of DNA damage to catch 
late variations in activation of these signals that might be important in mediating 
cell fate. There are conflicting reports regarding the timing of MAPK (ERK, JNK 
and p38) activation following genotoxic stress with hints that significant activation 
does not occur before 48 hours following DNA damage (Bose, Motiwale et al. 
2005). However, Fritz et al. recently reported that JNK is activated, to levels up 
to 2.5-fold over saline-treated controls, by specific types of DNA damage within 8 
hours of damage induction by alkylating agents such as MMS (Fritz and Kaina 
2005). In light of this, the absence of any significant observed JNK activation in 
this experiment set is troubling and leads to concerns over the reliability and 
sensitivity of the antibodies used to detect activated JNK and ERK proteins. 
Cellular Response 
Changes in cell-cycle profile of cell populations treated with 5nM and 
50nM CLM were dramatic. In cells treated with 5nM CLM, the dramatic increase 
in the GUM population and the near abolition of the G I  population at 24 hours 
following treatment (Fig. 22, middle left and middle center), taken together, 
suggest the initiation of a strong G2lM checkpoint in these populations. 
In cells treated with 50nM CLM, these same trends in G I  and G21M 
populations present themselves at 24 hours following treatment, though the shifts 
in population percentages are far less dramatic than those in the 5nM CLM- 
treated populations (Fig. 22, bottom left and bottom middle). These population 
shifts again suggest the initiation of a G2lM checkpoint in cell populations treated 
with 50nM CLM. The lack of as dramatic a build-up in the G2lM population and 
decrease in G I  population in the 50nM CLM-treated population as in the 5nM 
CLM-treated population, despite this G2lM checkpoint, suggests that a G I  cell- 
cycle checkpoint may also be active in cell populations treated with 50nM CLM. 
At 48 hours following treatment with 50nM CLM, GI ,  S and G2lM 
population percentages dramatically deceased from levels at 24 hours following 
treatment (Fig. 22, bottom right and bottom middle). Additionally, a very large 
sub-GI population developed (45% of the population), indicating a large amount 
of cell death in these populations. Taken together, these trends suggest that all 
cell-cycle checkpoints are over-ridden by 48 hours following treatment in cell 
populations treated with 50nM CLM, allowing cells to either proceed through the 
cell cycle to mitosis before dying by mitotic catastrophe, or to exit the cell cycle 
directly to die. 
These observations are interesting. They suggest that low dose CLM is 
capable of strongly inducing a G2lM checkpoint. Also suggested is that the high 
dose of CLM is capable of inducing both G2lM and GI-phase checkpoints, but 
that no checkpoints are maintained by 48 hours in populations treated with 50nM 
CLM. The induction of cell cycle checkpoints is a rapid process mediated by 
signaling transduced by post translational modifications (O'Connell, Walworth et 
al. 2000). This response is strongly activated by both low and high dose CLM. 
However, maintenance of cell cycle checkpoints requires transcription and 
translation of new proteins, especially the p21 cdk inhibitor (Yoon, Chen et al. 
2003). CLM-treated cells may well be unable to support such transcription due to 
lesions created in the genome that are critical for such transcription (eg at the 
p21 locus) (Khanna and Jackson 2001). Such an inability to transcribe key 
checkpoint maintenance factors would plausibly account for the inability of CLM- 
treated cells to maintain cell cycle checkpoints. 
It is also interesting to note the dramatic difference in cell death induced 
by low (5nM) and high (50nM) CLM-treatment (5% in 5nM, 45% in 50nM, as 
compared to 3% in untreated populations at 48 hours following treatment) (Fig. 
20). However, there is a large buildup in the aneuploid population in cell 
populations treated with 5nM CLM (26% in 5nM, 12% in 50nM populations, 
versus 14% in untreated populations) (Fig. 228, right panel). It has been 
observed that cells may die by mitotic catastrophe following induction of DNA 
double-strand breaks (DSB), both in vitro and in vivo, and that death by this route 
is preceded by several abnormal mitoses without cell division, leading to 
aneuploid cells (Mekid, Tounekti et al. 2003). This may explain the 
microscopically observed high levels of mitotic cells in the treated populations at 
differential time points and suggests that this aneuploid population is on its way 
to death via mitotic catastrophe. If this hypothesis is correct, we would predict 
that a similar build up in aneuploid cells occurred in the 50nM population 
preceeding the observed high levels of cell death, most likely occurring at a 
timepoint shortly after 24 h (the time at which high levels of mitosis were 
observed). 
Future Work 
The response to a cytotoxic lesion such as a DSB requires that cell 
processes come to a halt (i.e. that cell cycle, cell growth, general protein 
translation and other metabolic activities stop) and drastically switch focus to 
allow for repair processes and subsequent re-entry into the cell-cycle, or death 
(Bose, Motiwale et al. 2005). The signal transduction mechanisms that must 
coordinate such a drastic rewiring and return, or end, of so many cellular 
processes are incredibly complex. 
It will be very interesting to learn how information flow through these 
networks mediates the drastically various responses. We will initially attempt a 
partial least squares (PLS)-based analysis of this data in order to extract novel 
relationships between signaling parameters andlor groups of signaling 
parameters and response. In the future, we plan to expand data collection by 
high throughput In-cell western. Signals to be measured will be expanded to 
include several more key network signaling components (eg MAPKAPK2lChk3, 
CDC25 family members, Cdks, Akt (see Fig.1)). These proteins are known to 
play an important role in mediating such cell fate decisions cell cycle arrest 
(cdks) and survival (Akt). The signaling and response to a broader range of cues 
will be measured in order to stretch the dynamic range of both signaling and 
response values in the context of this network and to better train a robustly 
predictive model. The development of predictive tests for cell response to DSB 
from such a model would be extremely relevant to cancer therapy as such tests 
would help to identify agents that are potentially effective and those that will most 
likely not be effective, or have too great a potential for insupportable side-effects. 
Finally, the relationships we are able to identify from these statistical models will 
allow us to contruct new deterministic physico-chemical models of this system 
andlor to improve such existing models. 
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V. Figure Captions 
Figure 1. DNA damage signaling network 
Figure 2. 
(A) Chemical structure of calicheamicin (CLM). High-lighted in red is the 10-member 
enediyne ring structure. This enediyne structure is thought to undergo the Bergman 
cyclization reaction in B, below, following a nucleophilic attack on the central sulfur in 
the methyl trisulfide substituent group in CLM (illustration taken from the faculty 
website of Liang, 2.-X. Assistant Professor, NTU School of Biological Sciences. 2005). 
(B) Schematic for the thermal cycloaromatization reaction of enediynes, first 
characterized by Bergman. One of the intermediates in this reaction (2) is a highly 
reactive di-radical species. It is this species that is thought to be responsible for the 
ability of CLM to simultaneously abstract hydrogen atoms from opposite DNA strands at 
sufficiently close proximity to result in a DNA double-strand break (illustration taken 
from Nicolaou and Yue, 1993). 
Figure 3. Antibody Dilution Experimental Set-up, Determining the optimal antibody 
dilution of up to two antibodies simultaneously 
(A) U20S cells were seeded at 10,000 cells per well in a total volume of 200ul of total 
media in 96-well tissue-culture treated plates, all wells on the edge of the plate were filled 
with an equal volume of media, but were not seeded 
(B) Following overnight incubation at 37OC, cells were treated or not with activating 
treatments as described in Materials and Methods for each antibody, and according to the 
above schematic 
(C) Following fixation, cells were immuno-stained with antibody dilutions ranging from 
1 5 0  to 1:5000 (150, 1: 100, 1:250, 1500, 1:1000, 1:2000, 1:5000 and 0) as described in 
Materials and Methods and according to the above schematic 
Figure 4. Cell Number Dilution Experimental Set-up, Determining Linear Range of 
detection for up to two antibodies simultaneously 
(A) U20S cells were seeded in dilutions ranging from 10,000 cells/well to 2,000 
cells/we11(10,000,8,000,6,000,4,000,2,000 and 0) in a total volume of 200ul of total 
media in 96-well tissue-culture treated plates according to the above schematic, all wells 
on the edge of the plate were filled with an equal volume of media, but were not seeded 
(B) Following overnight incubation at 37OC, cells were treated or not with activating 
treatments as described in Materials and Methods for each antibody, and according to the 
above schematic 
(C) Following fixation, cells were immuno-stained with antibody at the optimal antibody 
concentration determined from previous Antibody Dilution experiments 
Figure 5. Time-course Cellular Signaling Experiments: Time-point Experimental Set- 
up for up to seven antibodies simultaneously 
(A) U20S cells were seeded at 6,000 cells per well in a total volume of 200ul of total 
media in 96-well tissue-culture treated plates, all wells in the first and last column of the 
plate were filled with an equal volume of media, but were not seeded 
(B) Following overnight incubation at 37OC, cells were treated with 0,5 or 50nM 
calicheamicin (CLM) as described in Materials and Methods and according to the above 
schematic 
(C) Following fixation, cells were imrnuno-stained with antibodies at their respective 
optimal dilutions previously determined from Antibody Dilution experiments, according 
to the above schematic 
Figure 6. Positive Control Experimental Set-up for phospho-ATM, Chk2, and H2AX 
(A) U20S cells were seeded at 6,000 cells per well across only three rows, excluding 
edge wells according to the above schematic, all remaining wells were filled with an 
equal volume of media, but were not seeded 
(B) Following overnight incubation at 37OC, cells were treated or not for 15 minutes 
with lOOnM CLM (the activating treatment corresponding to these target phospho- 
proteins, as described in Materials and Methods) 
(C) Following fixation, cells were immuno-stained with phospho-ATM, Chk2 or H2AX 
antibodies at their respective optimal dilutions 
Figure 7. Positive Control Experimental Set-up for phospho-JNK and p38 
(A) U20S cells were seeded at 6,000 cells per well across only two rows, excluding edge 
wells, according to the above schematic, all remaining wells were filled with an equal 
volume of media, but were not seeded 
(B) Following overnight incubation at 37OC, cells were treated or not for 30 minutes 
with 5001nM NaCl (the activating treatment corresponding to these target phospho- 
proteins, as described in Materials and Methods) 
(C) Following fixation, cells were imrnuno-stained with phospho-JNK or p38 antibodies 
at their respective optimal dilutions 
Figure 8. Positive Control Experimental Set-up for phospho-p53 and ERK 
(A) U20S cells were seeded at 6,000 cells per well across only two rows, excluding edge 
wells, according to the above schematic, all remaining wells were filled with an equal 
volume of media, but were not seeded 
(B) Following overnight incubation at 37OC, cells in the first row were treated or not for 
12 hours with lOuM doxorubicin (DOX), (the activating treatment corresponding to the 
target phospho-protein, phospho-p53, as described in Materials and Methods), while cells 
in the second row were serum starved for 12 hours and then treated or not for 10 minutes 
with lOOnM PMA (the activating treatment corresponding to the target phospho-protein, 
phospho-ERK, as described in Materials and Methods) 
(C) Following fixation, cells in the first and second row were respectively immuno- 
stained with phospho-p53 and phospho-ERK antibodies at their respective optimal 
dilutions 
Figure 9. Traditional Western Blots are not sufficient to ensure Antibody specificity and 
affinity in the In-Cell Western Format 
(A) Traditional western blot with phospho-Akt antibody from CST, #4056, shows high 
specificity and affinity for phospho-Akt 
(B) In-cell western using the same phospho-Akt antibody (CST #4056), shows high 
background, indicates that this antibody lacks sufficient specificity to be a usefuf reagent 
for detection of phospho-Akt in this assay format 
Figure 10. Phospho-ATM antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells untreated (-) or treated (+) with activating treatment for phospho-ATM, 
immuno-stained with primary antibody dilutions of phospho-ATM antibody (pictured, 
fiom top: 1:50, 1 : 100, 1 :250, 1500, 1:5000,0) and secondary antibody (IRDye 800CW 
Donkey anti-Mouse, at 1:500), detected on the Odyssey Scanner in the 800nm channel, 
pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, shows the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects. The 
arrow indicates the point of optimal antibody amount in the well for this antibody (where 
the rate of increase in signal to background is maximum) and corresponds to an optimal 
antibody dilution of 1500 for the phospho-ATM antibody of original concentration 
1 uglul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-ATM, immuno-stained with primary antibody at the optimal antibody dilution 
of 1:500, determined in A above (pictured, from top: 10,000, 8,000,6,000,4,000,2,000 
and 0 cells plated per well) and secondary antibody (IRDye 800CW Donkey anti-Mouse, 
at 1 :500), detected on the Odyssey Scanner in the 800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, shows the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nm channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects. 
(C)Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.9883 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 8,000 cells plated per well 
Figure 11. Phospho-Chk2 antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells not treated (-) or treated (+) with activating treatment for phospho- 
Chk2, immuno-stained with primary antibody dilutions of phospho-Chk2 antibody 
(pictured, fiom top: 1 50,  1 : 100, 1 :250, 1 500, 1 :5000 and 0) and secondary antibody 
(IRDye 800CW Goat anti-Rabbit, at 1:500), detected on the Odyssey Scanner in the 
800nm channel, pseudo-colored green; 
right panel: Data fiom the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects. The 
arrow indicates the point of optimal antibody amount in the well for this antibody (where 
the rate of increase in signal to background is maximum) and corresponds to an optimal 
antibody dilution of 1 :250 for the phospho-Chk2 antibody of original concentration 
0.1 uglul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-Chk2, immuno-stained with primary antibody at the optimal antibody dilution 
of 1:250, determined in A above (pictured, fiom top: 10,000, 8,000,6,000,4,000,2,000 
and 0 cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1 :500), detected on the Odyssey Scanner in the 800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nm channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects. 
(C) Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.9992 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 6,000 cells plated per well 
Figure 12. Phospho-H2AX antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells not treated (-) or treated (+) with activating treatment for phospho- 
H2AX, immuno-stained with primary antibody dilutions of phospho-H2AX antibody 
(pictured, from top: 150, 1 : 100, 1 :250, 1:500, 1 :5000 and 0) and secondary antibody 
(IRDye 800CW Goat anti-Rabbit, at 1:500), detected on the Odyssey Scanner in the 
800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects. The 
arrow indicates the point of optimal antibody amount in the well for this antibody (where 
the rate of increase in signal to background is maximum) and corresponds to an optimal 
antibody dilution of 1 :200 for the phospho-H2AX antibody of original concentration 
0.1 uglul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-H2AX, immuno-stained with primary antibody at the optimal antibody dilution 
of 1:200, determined in A above (pictured, fi-om top: 10,000,8,000,6,000,4,000,2,000 
and 0 cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1:500), detected on the Odyssey Scanner in the 800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nm channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects. 
(C)Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.967 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 6,000 cells plated per well 
Figure 13. Phospho-JNK antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells not treated (-) or treated (+) with activating treatment for phospho-JNK, 
immuno-stained with primary antibody dilutions of phospho-JNK antibody (pictured, 
fi-om top: 1 50,  1 : 100, 1 :250, 1 500, 1 5000 and 0) and secondary antibody (IRDye 
800CW Goat anti-Rabbit, at 1:500), detected on the Odyssey Scanner in the 800nm 
channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects. The 
arrow indicates the point of optimal antibody amount in the well for this antibody (where 
the rate of increase in signal to background is maximum) and corresponds to an optimal 
antibody dilution of 1 : 100 for the phospho-JNK antibody of original concentration 
0.1 uglul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-JNK, immuno-stained with primary antibody at the optimal antibody dilution of 
1 : 100, determined in A above (pictured, from top: 10,000, 8,000,6,000,4,000,2,000 and 
0 cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1:500), detected on the Odyssey Scanner in the 800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nrn channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects. 
(C) Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.99 13 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 6,000 cells plated per well 
Figure 14. Phospho-p3 8 antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells not treated (-) or treated (+) with activating treatment for phospho-p38, 
immuno-stained with primary antibody dilutions of phospho-p38 antibody (pictured, 
from top: 150, 1 : 100, 1 :250, 1500, 1:5000 and 0) and secondary antibody (1RDye 
800CW Goat anti-Rabbit, at 1 :500), detected on the Odyssey Scanner in the 800nm 
channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects. The 
arrow indicates the point of optimal antibody amount in the well for this antibody (where 
the rate of increase in signal to background is maximum) and corresponds to an optimal 
antibody dilution of 1 : 100 for the phospho-p38 antibody of original concentration 
0.1 uglul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-p38, irnmuno-stained with primary antibody at the optimal antibody dilution of 
1 : 100, determined in A above (pictured, from top: 10,000, 8,000,6,000,4,000,2,000 and 
0 cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1 :500), detected on the Odyssey Scanner in the 800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nm channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects. 
(C) Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.99 15 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 8,000 cells plated per well 
Figure 15. Phospho-ERK antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells not treated (-) or treated (+) with activating treatment for phospho-ERIC, 
immuno-stained with primary antibody dilutions of phospho-ERK antibody (pictured, 
from top: 150, 1 : 100, 1 :250, 1:500, 1:5000 and 0) and secondary antibody (1RDye 
800CW Goat anti-Rabbit, at 1:500), detected on the Odyssey Scanner in the 800nm 
channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects. The 
arrow indicates the point of optimal antibody amount in the well for this antibody (where 
the rate of increase in signal to background is maximum) and corresponds to an optimal 
antibody dilution of 1 : 100 for the phospho-ERK antibody of original concentration 
0.1 uglul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-ERK immuno-stained with primary antibody at the optimal antibody dilution of 
1 : 100, determined in A above (pictured, from top: 10,000, 8,000, 6,000,4,000,2,000 and 
0 cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1:500), detected on the Odyssey Scanner in the 800nm channel, pseudo-colored green; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nm channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects. 
(C) Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.9795 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 8,000 cells plated per well 
Figure 16. Phospho-p53 antibody validation 
(A) Antibody dilution experiments: 
left panel: Cells not treated (-) or treated (+) with activating treatment for phospho-p53, 
concurrently stained with Topro-3 Iodide DNA stain (1 :2500 dilution) and immuno- 
stained with primary antibody dilutions of phospho-p53 antibody (pictured, from top: 
1 50,  1 : 100, 1 :250, 1 500, 1 5000 and 0) and secondary antibody (IRDye 800CW Goat 
anti-Rabbit, at 1500); p53 immuno-stain is detected on the Odyssey Scanner in the 
800nm channel, pseudo-colored green; 
middle panel: Cells not treated (-) or treated (+) with activating treatment for phospho- 
p53, concurrently stained with Topro-3 Iodide DNA stain (1 :2500 dilution) and immuno- 
stained with primary antibody dilutions of phospho-p53 antibody (pictured, from top: 
150, 1 : 100, 1 :250, 1500, 1:5000 and 0) and secondary antibody (1RDye 800CW Goat 
anti-Rabbit, at 1:500); Topro-3 Iodide DNA stain is detected on the Odyssey Scanner in 
the 700nm channel, pseudo-colored red; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the amount of antibody in 
the well in both untreated (-) and treated (+) cell populations. Antibody signal intensity 
indicates the Raw Integrated Intensity of signal detected in the well in the 800nm channel 
at each antibody dilution, minus the Raw Integrated Intensity of signal detected in the 
800nm channel in wells with no primary antibody, to correct for background effects, and 
normalized to amount of DNA detected in the wells, to correct for cell number variation 
in wells containing treated vs. untreated cells. The arrow indicates the point of optimal 
antibody amount in the well for this antibody (where the rate of increase in signal to 
background is maximum) and corresponds to an optimal antibody dilution of 1 :500 for 
the phospho-p53 antibody of original concentration O.lug/ul 
(B) Cell number dilution experiments: 
left panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-p53 concurrently stained with Topro-3 Iodide DNA stain (1 :2500 dilution) and 
immuno-stained with primary antibody at the optimal antibody dilution of 1 :500, 
determined in A above (pictured, from top: 10,000,8,000,6,000,4,000,2,000 and 0 
cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1:500); p53 immuno-stain is detected on the Odyssey Scanner in the 800nm channel, 
pseudo-colored green; 
middle panel: Cell dilutions untreated (-) or treated (+) with activating treatment for 
phospho-p53 concurrently stained with Topro-3 Iodide DNA stain (1 : 25 00 dilution) and 
immuno-stained with primary antibody at the optimal antibody dilution of 1 :500, 
determined in A above (pictured, from top: 10,000, 8,000,6,000,4,000,2,000 and 0 
cells plated per well) and secondary antibody (IRDye 800CW Goat anti-Rabbit, at 
1 :500); Topro-3 Iodide stain is detected on the Odyssey Scanner in the 700nm channel, 
pseudo-colored red; 
right panel: Data from the image in the left panel, quantified and plotted, showing the 
Antibody signal intensity, in arbitrary units, as a function of the cell number plated per 
well in untreated (-) and treated (+) cell populations. Antibody signal intensity indicates 
the Raw Integrated Intensity of signal detected in the well in the 800nm channel at each 
cell number dilution, minus the Raw Integrated Intensity of signal detected in the 800nm 
channel in wells with no cells plated, to correct for background effects, and normalized to 
amount of DNA detected in the wells, to correct for cell number variation in wells 
containing treated vs. untreated cells.. 
(C) Antibody signal intensity as a function of the cell number plated per well in the 
treated cell population only. The R~ value of 0.9969 for the linear fit demonstrates 
linearity of detected signal with respect to target protein concentration in the wells over 
the range of protein concentration represented by 0 to 6,000 cells plated per well 
Figure 17. Time-course of cellular signaling (fold activation of phospho-proteins) for 
cells treated with 0,5 or 50nM CLM. Fold activation indicates the fold increase in 
phospho-protein level over the phospho-protein level detected at time 0 (corresponding to 
no treatment, see Materials and Methods). 
(A) OnM CLM treatment: 
left panel: early time-points (0-240 minutes) 
right panel: full time-course (0-26.5 hours) 
For each of the phospho-proteins (except phospho-ATM), each point represents the 
average of eight biological replicates from two experiments separated in time. For 
phospho-ATM, each point represents the average of four biological replicates from one 
experiment. 
(B) 5nM CLM treatment: 
left panel: early time-points (0-240 minutes) 
right panel: full time-course (0-26.5 hours) 
For each of the phospho-proteins (except phospho-ATM), each point represents the 
average of six biological replicates from two experiments separated in time. For 
phospho-ATM, each point represents the average of three biological replicates from one 
experiment. 
(C) 50nM CLM treatment: 
left panel: early time-points (0-240 minutes) 
right panel: full time-course (0-26.5 hours) 
For each of the phospho-proteins (except phospho-ATM), each point represents the 
average of six biological replicates from two experiments separated in time. For 
phospho-ATM, each point represents the average of three biological replicates from one 
experiment. 
Figure 18. Dose-responsive Cellular-signaling, comparing the fold activation of 
phospho-proteins in cells treated with 0, 5 and 50nM CLM. Fold activation indicates the 
fold increase in phospho-protein level over the phospho-protein level detected at time 0 
(corresponding to no treatment, see Materials and Methods). 
(A) left panel: phospho-ATM, right panel: phospho-Chk2 
(B) left panel: phospho-H2AX, right panel: phospho-JNK 
(C) left panel: phospho-p38, right panel: phospho-ERK 
(D) left panel: phospho-p53 
Figure 19. FACS-based cleaved caspase-3 detection as a read-out for apoptosis 
(representative plots). The horizontal pink line in each plot separates cell populations 
with low cleaved caspase-3 (viable) from cell populations with high cleaved caspase-3 
(apoptotic). 
Upper left: cells treated with OnM CLM after 12 hours (negative control), 99.3% of the 
population is viable 
Lower left: cells treated with 50nM CLM after 12 hours, 2.6% of the population is 
apoptotic 
Lower middle: cells treated with 50nM CLM after 24 hours, 24.2% of the population is 
apoptotic 
Lower right: cells treated with 50nM CLM after 48 hours, 59.9% of the population is 
apoptotic 
Figure 20. FACS-based cleaved caspase-3 detection as a read-out for apoptosis, for cells 
treated with 0 ,5  and 50nM CLM at 12,24 and 48 hours. Data from plots is quantified 
and plotted. 
Figure 21. Example of cell-cycle profiles determined by relative propidium iodide 
incorporation in the population for cells treated with 0, 5 or 50nM CLM at 12,24 and 48 
hours following treatment. Plots are based on whole cell data only (debris gated out) and, 
within this population, all cells are expected to fall into one of five classes: the sub-GI 
population (dead), the G1 population (2N), the S phase population, the G2lM population 
(4N) or the aneuploid population (> 4N). Each plot is explicitly divided into four areas 
that are quantified and represent, from left, the sub-GI population (dead), the G1 
population (2N), the G2/M population (4N) and the aneuploid population (> 4N). The 
percentage of the total cell population in S phase was determined by subtracting the 
percentages of cells in all other populations from 100 percent. 
Figure 22. Cumulative analysis of cell-cycle profiles from four separate experiments as 
determined by relative propidium iodide incorporation in the population for cells treated 
with 0,5 or 50nM CLM at 12,24 and 48 hours following treatment. Data from the plots 
(Figure 2 1) is quantified and visualized. 
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